Clinical trial register · Spain

Clinical Trials in Madrid, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Spain and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV

Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5875 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:18 UTC

5875

Studies in scope

all four open statuses

3096

Recruiting now

open to new participants

1137

Lead sponsors

across recruiting studies

Top sites

Barcelona 3238 Madrid 3046 Valencia 1215 Seville 1054 Málaga 746

Trials with a site in Madrid

Status

Study

Lead sponsor

Phase

Enrol

Sites in Spain

Start

Active, closed

A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis

NCT06744920Generalized Myasthenia Gravis

DrugRemibrutinib

Novartis Pharmaceuticals

Phase 3

180

Barcelona, Lleida, Madrid, Málaga, Valencia

2025-02-07

Active, closed

A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps

NCT06834360Chronic Rhinosinusitis With Nasal Polyps

DrugsItepekimab·Mometasone furoate

Sanofi

Phase 3

216

Barcelona, Santander, L'Hospitalet de Llobregat, Pamplona, Madrid

2025-02-06

Recruiting

Robotic Rehabilitation of the Upper Limb in Subacute Stroke

NCT06839482Stroke

IRCCS San Raffaele Roma

Not applicable

130

Madrid

2025-02-06

Recruiting

A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum

NCT06624670Pyoderma Gangrenosum

DrugsSpesolimab·Prednisolone·Prednisone

LEO Pharma

Phase 3

Barcelona, Madrid, Málaga

2025-02-05

Recruiting

Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure

NCT06651970Chronic Lymphocytic Leukaemia, Moderate to Severe Cardiac Impairment

DrugAcalabrutinib

AstraZeneca

Phase 4

Barcelona, Madrid, Seville

2025-02-04

Recruiting

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

NCT06618287Lung Cancer, Breast Cancer

DrugsPumitamig·Iza-bren·Osimertinib·Opdivo

Bristol-Myers Squibb

Phase 1/2

416

Santiago de Compostela, Barcelona, Hospitalet, Madrid, Majadahonda, Valencia, Málaga, Seville

2025-02-04

Recruiting

Efficacy and Safety of Zelpultide Alfa in Preterm Neonates at High Risk of Developing Bronchopulmonary Dysplasia (BPD)

NCT06897839Bronchopulmonary Dysplasia

Airway Therapeutics, Inc.

Phase 2/3

366

Alicante, Barcelona, Bilbao, Cadiz, Lleida, Madrid, Málaga, Santiago de Compostela

2025-02-03

Active, closed

A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)

NCT06812325Thyroid Eye Disease (TED)

DrugVRDN-003

Viridian Therapeutics, Inc.

Phase 3

320

A Coruña, Barcelona, Córdoba, Madrid, Navarrés, Seville, Zaragoza

2025-02-03

Recruiting

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

NCT06712355Extensive-stage Small-cell Lung Cancer

DrugsPumitamig·Etoposide·Atezolizumab·Carboplatin

BioNTech SE

Phase 3

621

Badajoz, Barcelona, Castellon, León, Madrid, Málaga, Seville, Torrejón de Ardoz

2025-02-03

Recruiting

EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

NCT06556563Glioblastoma

DrugsTemozolomide·Keytruda·Pembrolizumab

NovoCure GmbH

Phase 3

741

Madrid, Barcelona, Córdoba, Granada, Seville, Valencia

2025-02-03

Recruiting

Study to Assess the Safety and Effectiveness of Beltaven® in Patients With Allergy to Apis Mellifera, Polistes Dominula or Vespula Spp.

NCT07309822Allergy

Probelte Pharma S.L.U.

Observational

Barcelona, Castellon, Ciudad Real, Córdoba, Girona, Lleida, Madrid, Orihuela

2025-02-01

Recruiting

Follow-up of Spanish Prospective Asthma and Nasal Polyposis Registry

NCT06163807Chronic Asthma

Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz

Observational

1,200

Santiago de Compostela, Badalona, Barcelona, A Coruña, Madrid, Pamplona

2025-02-01

Not yet open

Prevention of Postsurgical Chronic Pain in Children and Adolescents (PREVENDOL)

NCT06638437Chronic Postsurgical Pain, Chronic Post-surgical Pain, Chronic Postoperative Pain, Chronic Post-operative Pain

University Rovira i Virgili

Not applicable

125

Barcelona, Madrid, Tarragona

2025-02-01

Not yet open

Knowledge of Vascular Age Contributes to Improve the Collaboration Between Community Pharmacies and Primary Health Care Physicians in Reducing Blood Pressure in Hypertensive Patients.

NCT06761235Hypertension and Cardiovascular Risk Factors

Enrique Rodilla

Not applicable

1,246

Sagunto (valencia), Madrid, Salamanca

2025-02-01

Not yet open

Dietary Supplements for Reduction of Intestinal Permeability Levels

NCT06760377Intestinal Permeability, Leaky Gut Syndrome, Zonulin

Universidad Complutense de Madrid

Not applicable

Madrid

2025-02-01

Recruiting

Impact of Virtual Reality Physiotherapy on Multiple Sclerosis Patients

NCT06735053Multiple Sclerosis

European University of Madrid

Not applicable

Móstoles, Madrid

2025-02

Recruiting

An Ex-US Study to Assess Treatment Persistence With Risankizumab in Adult Participants With Psoriatic Arthritis

NCT06764693Psoriatic Arthritis

AbbVie

Observational

1,200

Málaga, Lorca, Vigo, Seville, Granada, Huelva, Madrid, Murcia

2025-01-31

Active, closed

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)

NCT06799000Hidradenitis Suppurativa

DrugRemibrutinib

Novartis Pharmaceuticals

Phase 3

588

Cadiz, Badalona, Sabadell, Barcelona, Manises, Valencia, Madrid

2025-01-31

Recruiting

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

NCT06564038Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma, Large B-cell Lymphoma

DrugsSurovatamig·Acalabrutinib·Vincristine·Doxorubicin

AstraZeneca

Phase 1/2

408

Barcelona, Madrid, Palma de Mallorca, Santiago de Compostela, Valencia

2025-01-30

Active, closed

Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)

NCT06710132Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer

DrugM9140

EMD Serono Research & Development Institute, Inc.

Phase 1/2

184

Córdoba, Badalona, Barcelona, L'Hospitalet de Llobregat, Madrid, Pozuelo de Alarcón, Seville, Valencia

2025-01-29

Recruiting

FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

NCT06788990Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma

DrugsFicerafusp alfa·Keytruda·Pembrolizumab

Bicara Therapeutics

Phase 2/3

650

Badalona, Barcelona, Madrid, Pamplona, Santander, Valencia

2025-01-28

Recruiting

A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia

NCT06767683Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia

DrugALKS 2680

Alkermes, Inc.

Phase 2/3

786

Madrid, Barcelona

2025-01-27

Recruiting

Airway Coach Project: Prediction of Videolaryngoscopy Strategy With Clinical and Ultrasound Parameters (Multicentric)

NCT06881589Difficult Videolaryngoscopy

Clinica Universidad de Navarra, Universidad de Navarra

Observational

210

Madrid

2025-01-27

Recruiting

Effect of Oxygen Administration in the Non-dependent Lung on Postoperative Complications After Lung Surgery

NCT07461779Lung Resection Surgery, Anesthesia General

Francisco Andres de la Gala

Phase 4

177

Madrid

2025-01-27

Recruiting

A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease

NCT06100289Ulcerative Colitis, Crohn's Disease

DrugVedolizumab

Takeda

Phase 3

Ferrol, Madrid, Seville, Valencia

2025-01-22

Active, closed

Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma

NCT06478212IDH1-mutant Glioma, IDH2-mutant Glioma

DrugsVorasidenib·Temozolomide

Institut de Recherches Internationales Servier

Phase 1/2

Barcelona, Madrid

2025-01-22

Recruiting

A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

NCT06585774Chronic Graft-versus-host-disease

DrugsAxatilimab·Methylprednisolone·Prednisolone·Prednisone

Incyte Corporation

Phase 3

240

Barcelona, Donostia / San Sebastian, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Madrid, Majadahonda, Salamanca, Seville

2025-01-21

Active, closed

PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer

NCT06133517Urothelial Bladder Carcinoma

DrugsDomvanalimab·Zimberelimab·Sacituzumab Govitecan

Fundación para el Progreso de la Oncología en Cantabria

Phase 2

L'Hospitalet de Llobregat, Santander, Madrid, Pamplona, Toledo, Valladolid

2025-01-20

Active, closed

Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)

NCT06632951Urothelial Carcinoma

DrugsLivmoniplimab·Budigalimab·Docetaxel·Gemcitabine

AbbVie

Phase 2

150

Barcelona, Madrid, Seville

2025-01-20

Recruiting

Ablation of Human Cardiac Fibrillation Based on Models of Hierarchical Organization of Tissue Excitation

NCT07390175Atrial Fibrillation (AF), Ablation Treatment, TerFib_Hyerarchy

Hospital San Carlos, Madrid

Not applicable

Madrid

2025-01-20

Active, closed

Clinical Study to Evaluate Debio0123 + Sacituzumab Govitecan Combination in TNBC or HR+/HER2- Advanced Breast Cancer

NCT06612203Advanced Breast Cancer

DrugSacituzumab Govitecan

MedSIR

Phase 1/2

Barcelona, Granada, Madrid, Málaga, Valencia

2025-01-17

Recruiting

A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

NCT06680830Parkinson Disease, Parkinson, Idiopathic Parkinson Disease, Early Parkinson Disease (Early PD)

Neuron23 Inc.

Phase 2

150

San Sebastián, Barakaldo, Barcelona, Madrid, Móstoles, Seville

2025-01-17

Recruiting

A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants With Spinal Muscular Atrophy (PIERRE-PK)

NCT06555419Muscular Atrophy, Spinal

DrugNusinersen

Biogen

Phase 1

Madrid, Valencia

2025-01-16

Active, closed

A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome

NCT06684847Primary Sjogrens Disease

DrugEfgartigimod PH20

argenx

Phase 3

631

Vitoria-Gasteiz, Badajoz, Barcelona, Santiago de Compostela, Madrid, A Coruña, Seville, Valencia

2025-01-15

Recruiting

Antidiabetic Effect of Olive Pomace Oil

NCT06723886Type 2 Diabetes Mellitus, Prediabetes (Insulin Resistance, Impaired Glucose Tolerance), Prediabetic State, Diabetes

Instituto de Ciencia y Tecnología de Alimentos y Nutrición

Not applicable

Madrid

2025-01-15

Recruiting

Cirtuvivint in Selected Advanced Soft-Tissue Sarcomas

NCT07032285Soft Tissue Sarcoma (STS)

Asociación Europea y Latinoamericana SELNET para la Investigación en Sarcomas

Phase 2

Madrid

2025-01-15

Active, closed

A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms

NCT06618001Leukemia, Myeloid, Acute, Myelodysplastic Neoplasms

Janssen Research & Development, LLC

Phase 1

Barcelona, Madrid, Pamplona

2025-01-14

Recruiting

Evaluation of PreveCol's Efficiency As a Second Line Method for the Early Colorectal Cancer Detection

NCT06703632Screening for Colon Cancer, Blood Samples, Survey and Questionnaire, Colorectal Carcinoma

ADVANCED MARKER DISCOVERY S.L.

Not applicable

4,538

Madrid

2025-01-14

Active, closed

Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)

NCT06700343Relapsing-remitting Multiple Sclerosis (RRMS)

DrugOcrelizumab

Amgen

Phase 3

152

Alcorcón, Barcelona, Castilleja de la Cuesta, DÃ©nia, Madrid, Malag, Málaga, Salt

2025-01-13

Recruiting

An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors

NCT06589596Advanced Solid Tumor

DrugBGB-58067

BeOne Medicines

Phase 1

525

Barcelona, Madrid

2025-01-10

Recruiting

A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia

NCT06609226Sickle Cell Disease, Thalassemia

Novo Nordisk A/S

Phase 3

480

Barakaldo, Barcelona, Madrid

2025-01-10

Recruiting

An Open Label Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adults With Focal Onset or Tonic-Clonic Seizures

NCT06908356Focal Onset Seizure, Primary Generalized Epilepsy

Praxis Precision Medicines

Phase 2

Madrid

2025-01-10

Recruiting

A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis

NCT06807424Arthritis, Psoriatic

DrugIcotrokinra

Janssen Research & Development, LLC

Phase 3

750

A Coruña, Córdoba, L'Hospitalet de Llobregat, Madrid, Málaga, Santander, Santiago de Compostela, Seville

2025-01-09

Active, closed

Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis

NCT06846541Plaque Psoriasis, Psoriasis (PsO), Psoriasis, Moderate Psoriasis

Alumis Inc

Phase 3

1,680

Alicante, Barcelona, Madrid, A Coruña, Manises

2025-01-08

Active, closed

A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain

NCT06764186Locally Advanced or Metastatic Breast Cancer

DrugsCapivasertib·Fulvestrant

AstraZeneca

Phase 3

101

Alicante, Barcelona, Bilbao (Vizcaya), Córdoba, Donostia / San Sebastian, El Palmar, Girona, Madrid

2025-01-07

Active, closed

A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)

NCT06660654Advanced Solid Tumor, Metastatic Solid Tumors

DrugR-DXd

Daiichi Sankyo

Phase 2

335

A Coruña, Barcelona, Madrid, Málaga

2025-01-06

Recruiting

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCT06588478Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugPirtobrutinib

Loxo Oncology, Inc.

Phase 2

249

Barcelona, L'Hospitalet Del Llobregat, Madrid, Majadahonda, Marbella, Oviedo, Salamanca, Santander

2025-01-03

Recruiting

A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease

NCT06227910Crohn's Disease

DrugsVedolizumab·Upadacitinib

Takeda

Phase 3

396

Madrid, Palma, Pamplona, Santiago de Compostela, Valencia

2025-01-02

Recruiting

Doxecitin and Doxribthymine in Adult Subjects With Thymidine Kinase 2 (TK2) Deficiency

NCT06754098Thymidine Kinase 2 (TK2 ) Deficiency, Mitochondrial Myopathies

Cristina Domínguez González

Phase 2

Madrid

2025-01-01

Recruiting

Implementation of an Efferent Loop Stimulation Protocol Prior to Ileostomy Closure at La Paz University Hospital

NCT06974500Postoperative Ileus, Colorectal Cancer Control and Prevention, Stoma - Ileostomy

Hospital Universitario La Paz

Observational

Madrid

2025-01-01

By invitation

The Effectiveness of a Brief Early Intervention of Acute Stress Syndrome Stabilization Protocol for Victims of Sexual Violence (ASSYST-SV).

NCT07112040Acute Stress Symptoms, Sexual Violence

Universidad Complutense de Madrid

Not applicable

Madrid

2025-01-01

Not yet open

Telematic Intervention for Reversing Frailty Among Older Patients with Aortic Stenosis Undergoing Transcatheter Aortic Valve Intervention. the TELE-FRAIL TAVI Clinical Trial

NCT06742970Aortic Stenosis

Spanish Society of Cardiology

Not applicable

206

Madrid

2025-01

Recruiting

Mepolizumab and in Office-office Nasal Polypectomy in Patients With Chronic Rhinosinusitis (CRS).

NCT07814924Chronic Rhinosinusitis With Nasal Polyps

DrugMepolizumab

Instituto de Investigación Marqués de Valdecilla

Phase 4

Barakaldo, Jerez de la Frontera, Madrid, Salamanca, Santander, Seville, Valladolid

2024-12-31

Active, closed

A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine

NCT06619509Solid Tumours

Boehringer Ingelheim

Phase 2

Aragon, Madrid, Santiago de Compostela

2024-12-30

By invitation

A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring

NCT06788509Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes

DrugsJNJ-75348780·JNJ-87801493·JNJ-80948543·Ibrutinib

Janssen Research & Development, LLC

Phase 1

120

Barcelona, Madrid, Pamplona, Salamanca

2024-12-30

Active, closed

A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)

NCT06687369Non Squamous Non Small Cell Lung Cancer

DrugsEU sourced Keytruda·US-sourced Keytruda·Pemetrexed·Cisplatin

mAbxience Research S.L.

Phase 3

726

A Coruña, Barcelona, Madrid, Málaga, Murcia, Oviedo, Palma de Mallorca, Pontevedra

2024-12-30

Recruiting

LIDRISE Study: A Phase 3 Study on the Efficacy and Safety of STN1013800 (Oxymetazoline HCl 0.1% Eye Drops, Single Dose) in the Treatment of Acquired Blepharoptosis.

NCT06514612Acquired Blepharophimosis

Santen SAS

Phase 3

234

Granada, Madrid, Santiago de Compostela, Zaragoza

2024-12-30

Recruiting

Early Transcatheter Mitral Valve Repair After Myocardial Infarction

NCT06282042Acute Mitral Regurgitation

Fundación para la Investigación Biosanitaria del Principado de Asturias

Not applicable

250

Alicante, Barcelona, L'Hospitalet de Llobregat, Santander, Córdoba, Las Palmas de Gran Canaria, Madrid, Málaga

2024-12-24

Recruiting

A Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia

NCT06752668Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia

DrugORX750

Centessa Pharmaceuticals (UK) Limited

Phase 2

248

Madrid, Vitoria-Gasteiz

2024-12-23

Recruiting

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)

NCT06637423Non-Muscle Invasive Bladder Cancer

DrugSacituzumab tirumotecan

Merck Sharp & Dohme LLC

Phase 1/2

Málaga, Madrid

2024-12-20

Active, closed

A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma

NCT06604715Relapsed or Refractory Multiple Myeloma

Janssen Research & Development, LLC

Phase 1

Badalona, Barcelona, Madrid, Pamplona, Salamanca

2024-12-19

Active, closed

A Study to Investigate the Course of Synovial Hypertrophy in Patients With Haemophilia A on Efanesoctocog Alfa Prophylaxis

NCT06752850Haemophilia A (Moderate or Severe), Hemophilia, Classic, Haemophilia, Hemophilia

DrugEfanesoctocog alfa

Swedish Orphan Biovitrum

Phase 4

Barcelona, Madrid, Seville, Valencia

2024-12-19

Recruiting

REACH: RWE Retrospective Study to Evaluate Cenobamate Impact on Health Care Resource Utilization

NCT06922175Epilepsy With Uncontrolled Focal-onset Seizures

Aziende Chimiche Riunite Angelini Francesco S.p.A

Observational

200

Barcelona, Madrid, Valencia

2024-12-19

Recruiting

A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease

NCT06500702Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion

DrugsBrivekimig·Frexalimab·Rilzabrutinib

Sanofi

Phase 2

Seville, Barcelona, Córdoba, Madrid

2024-12-19

Recruiting

Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction

NCT06736574Heart Failure, Heart Failure With Reduced Ejection Fraction

Cytokinetics

Phase 3

1,800

A Coruña, Santiago de Compostela, Barcelona, L'Hospitalet de Llobregat, Úbeda, Lugo, Madrid, Majadahonda

2024-12-19

Active, closed

Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease

NCT06747572Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Vertex Pharmaceuticals Incorporated

Observational

401

Madrid

2024-12-19

Active, closed

A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy

NCT06742190Multifocal Motor Neuropathy (MMN), MMN

DrugsEmpasiprubart·Immunoglobulin·IVIG

argenx

Phase 3

154

Alicante, Badalona, Barcelona, Madrid, Málaga, San Sebastián

2024-12-18

Recruiting

A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease

NCT06727604Graves' Disease

DrugIMVT-1402

Immunovant Sciences GmbH

Phase 2

240

Badalona, Barcelona, Córdoba, Granada, Madrid, Pamplona, Seville

2024-12-17

Active, closed

Phase 2 Study of Rapcabtagene Autoleucel in Myositis

NCT06665256Idiopathic Inflammatory Myopathies

DrugRapcabtagene autoleucel

Novartis Pharmaceuticals

Phase 2

Santiago Compostela, Santander, Pamplona, Barcelona, Córdoba, Madrid, Málaga, Salamanca

2024-12-17

Recruiting

DEBSCAN-IVL. Drug Eluting Balloon or Drug Eluting Stent to Treat CAlcified Nodules After IntraVascular Lithotripsy.

NCT06657833Coronary Artery Disease

Fundación EPIC

Not applicable

128

Barcelona, Fuencarral-El Pardo, Galdakao, L'Hospitalet de Llobregat, León, Madrid, Moncloa-Aravaca, Pamplona

2024-12-17

Recruiting

A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors

NCT06747585Squamous Non-small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma

Alentis Therapeutics AG

Phase 1/2

170

PAU de Sanchinarro, Pozuelo de Alarcón, Barcelona, Madrid, Málaga, Seville, Valencia

2024-12-16

Recruiting

A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

NCT06679101Multiple Myeloma, Newly Diagnosed Multiple Myeloma

DrugsBelantamab mafodotin·Daratumumab·Lenalidomide·Dexamethasone

GlaxoSmithKline

Phase 3

520

Badalona, Barcelona, Gijón, Madrid, Málaga, Murcia, Salamanca, Santander

2024-12-16

Recruiting

The PERSEVERE Study

NCT06588634Pulmonary Embolism, Pulmonary Thromboembolism

Inari Medical

Not applicable

200

Barcelona, Madrid

2024-12-16

Recruiting

Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

NCT06784193Advanced or Metastatic ER+ HER2- Breast Cancer (mBC), Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC), Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Breast Cancer

DrugsPalazestrant·Fulvestrant

Olema Pharmaceuticals, Inc.

Phase 1

180

Barcelona, Madrid

2024-12-16

Recruiting

Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation

NCT06501625Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation

DrugsIvosidenib·Durvalumab·Gemcitabine·Cisplatin

Institut de Recherches Internationales Servier

Phase 1/2

Barcelona, Madrid

2024-12-16

By invitation

PrEveNtion of Biliary Events After Acute Pancreatitis in NonSUrgicaL PAtients: PENINSULA Trial

NCT06409741Acute Pancreatitis Due to Gallstones, Acute Pancreatitis

Hospital General Universitario de Alicante

Not applicable

126

Alicante, Córdoba, Madrid, Valencia, Valladolid

2024-12-16

Recruiting

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT06667076Carcinoma, Non-Small-Cell Lung

DrugsLazertinib·Amivantamab

Janssen Research & Development, LLC

Phase 2

480

Barcelona, Jerez de la Frontera, Madrid, Santiago de Compostela, Valencia

2024-12-16

Recruiting

Allogeneic Use of Expanded Mesenchymal Stem Cells Derived From Adipose Tissue (HC106), Female Urinary Incontinence Women Over 50 Years Old

NCT06738576Urinary Incontinence Stress

Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz

Phase 1

Coslada, Madrid, Móstoles, Valdemoro, Villalba

2024-12-16

Recruiting

Unveiling Malnutrition and Metabolic Changes in Lung Cancer Patients: Setting the Basis for Precision Nutrition Models.

NCT07486947Lung Cancer

Fundación Investigación E Innovación Biomédica Hospital Universitario Infanta Sofia-Henares

Observational

180

Madrid, San Sebastián de los Reyes

2024-12-15

Active, closed

A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

NCT06628310Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma

DrugsBudigalimab·Telisotuzumab Adizutecan·Fluorouracil·Leucovorin

AbbVie

Phase 2

185

Pamplona, Madrid, Ourense, Valencia

2024-12-13

Recruiting

First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

NCT06657222Advanced Solid Tumors, HNSCC, SCLC, NSCLC

Gilead Sciences

Phase 1/2

250

Barcelona, Madrid

2024-12-13

Active, closed

A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors

NCT06710847Neoplasms, Colorectal, Solid Tumor, Colon Cancer, Rectal Cancer

GlaxoSmithKline

Phase 1/2

Barcelona, Madrid, Málaga

2024-12-13

Recruiting

Phase III Study With an Autologous Dermo-epidermal Skin Substitute for the Treatment of Burns in Adults and Adolescents

NCT06745557Burns

DrugsDenovoSkin·Ehsg-Kf

CUTISS AG

Phase 3

Barcelona, Madrid, Valencia

2024-12-13

Active, closed

Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

NCT06608927Metastatic Pancreatic Ductal Adenocarcinoma

DrugsQuemliclustat·Nab-paclitaxel·Gemcitabine

Arcus Biosciences, Inc.

Phase 3

610

Barcelona, Elche, Girona, Madrid, Pamplona, Vigo, Zaragoza

2024-12-13

Active, closed

Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS)

NCT06675864Progressive Multiple Sclerosis

DrugRapcabtagene autoleucel

Novartis Pharmaceuticals

Phase 1/2

Barcelona, Madrid, Málaga

2024-12-12

Recruiting

A Multicenter, Open, Comparative Study on Vaginal Dysbiosis in Premenopausal Women (DISPALOMA)

NCT06668012Vaginal Dysbiosis

Procare Health Iberia S.L.

Not applicable

Barcelona, Madrid

2024-12-12

Recruiting

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

NCT06750094Colorectal Neoplasms

DrugsLeucovorin calcium/Levoleucovorin·Amivantamab·Erbitux·Avastin

Janssen Research & Development, LLC

Phase 3

700

Badajoz, Barcelona, Madrid, Málaga, Pamplona, Seville, Valencia

2024-12-12

Recruiting

Photofunctionalization With UVC

NCT06724107Implant Site Reaction

Universidad Complutense de Madrid

Not applicable

Madrid

2024-12-12

Recruiting

A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.

NCT05421858Candidemia, Candidiasis, Invasive

DrugsCaspofungin·Fosmanogepix·Fluconazole

Basilea Pharmaceutica

Phase 3

450

Seville, Barcelona, Madrid, Barakaldo

2024-12-11

Recruiting

EFFICACY OF REMOTE MONITORING OF PATIENTS WITH DIABETES UNDER INSULIN TREATMENT, BY USING Caaring SOFTWARE

NCT06794658Diabetes Mellitus

Persei Vivarium

Not applicable

200

Valladolid, Madrid

2024-12-11

Active, closed

A Study to Evaluate the Safety, Tolerability, and Effects on Blood and Urine Markers of Single Ascending Dose of GSK4771261 in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney Disease

NCT06734234Kidney Disease

DrugGSK4771261

GlaxoSmithKline

Phase 1

Barcelona, Madrid

2024-12-11

Active, closed

Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma

NCT06784648Melanoma Metastatic, Melanoma of Skin, Melanoma BRAF V600E/K Mutated, Melanoma Recurrent

DrugsIpilimumab·Keytruda·Pembrolizumab

BioInvent International AB

Phase 1/2

Barcelona, Madrid

2024-12-11

Recruiting

SURGICAL GUIDES EFFECTIVENESS

NCT06737289Atrophic Maxilla

Universidad Complutense de Madrid

Not applicable

Madrid

2024-12-11

Active, closed

A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.

NCT06637631Crohn's Disease

DrugBalinatunfib

Sanofi

Phase 2

260

Madrid, Seville

2024-12-10

By invitation

Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)

NCT06723106Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP), Behçet's Syndrome (BS), Dermatomyositis (DM)

DrugRAY121

Chugai Pharmaceutical

Phase 1

144

Pamplona, Madrid, Barcelona, Córdoba, Seville, Valencia

2024-12-09

Active, closed

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

NCT06691984Metastatic Castration-resistant Prostate Cancer

DrugsXaluritamig·Cabazitaxel·Abiraterone·Enzalutamide

Amgen

Phase 3

707

Málaga, Seville, Barcelona, Pamplona, Valencia, Madrid

2024-12-09

Active, closed

A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies

NCT06645886Hematologic Malignancies, Adult

DrugsKQB198·Dasatinib

Kumquat Biosciences Inc.

Phase 1

Málaga, L'Hospitalet de Llobregat, Madrid

2024-12-09

By invitation

Digital BIOmarkers for the Assessment of Motor Status in Parkinson's Disease Patients with CLInical and ThErapeutic Application

NCT06817772Parkinson Disease, Parkinson

Universidad Politecnica de Madrid

Observational

Madrid

2024-12-09

Active, closed

A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)

NCT06534983Muscle-invasive Urothelial Carcinoma

DrugsAutogene cevumeran·Opdivo·Nivolumab

Hoffmann-La Roche

Phase 2

L'Hospitalet de Llobregat, Sant Andreu de la Barca, Madrid, Seville, Zaragoza

2024-12-09

Recruiting

A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease

NCT06679140COVID-19 SARS-CoV-2 Infection

DrugIbuzatrelvir

Pfizer

Phase 3

2,330

A Coruña, Benalmádena, Córdoba, Badalona, Barcelona, Madrid, Vigo, Alicante

2024-12-08

Recruiting

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

NCT06667908Carcinoma, Non-Small-Cell Lung

DrugsJNJ-90301900·Durvalumab

Johnson & Johnson Enterprise Innovation Inc.

Phase 2

130

Madrid, Pamplona, Santiago de Compostela, Valencia

2024-12-06

By invitation

Bone Metabolism in Premenopausal Exercising Women

NCT06961773Contraception, Bone Metabolism, Low Energy Availability, Eumenorrhea

Universidad Politecnica de Madrid

Not applicable

Madrid

2024-12-05

Recruiting

MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)

NCT06534437Non-Hodgkin Lymphoma, B-cell

DrugGlofitamab

Ryvu Therapeutics SA

Phase 2

178

Barcelona, Madrid, Murcia, Pamplona, Salamanca, Seville, Zaragoza

2024-12-05

Active, closed

A Long-term Safety and Efficacy Study of N-Acetyl-GED-0507-34-LEVO Gel 5%, in Subjects With Acne Vulgaris (GEDACNE-LT)

NCT07389109Acne Vulgaris

PPM Services S.A.

Phase 3

400

Alcorcón, Barcelona, Esplugues de Llobregat, Granada, Madrid, Málaga, Seville, Valencia

2024-12-05

Recruiting

Outcomes of Low-Risk Endometrial Cancer With Isolated Tumor Cells in the Sentinel Lymph Nodes: A Prospective, Multicenter, Single-Arm Observational Study

NCT06689956FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, Stage IA1 Endometrial Cancer FIGO 2023, Stage IA2 Endometrial Cancer FIGO 2023

Mayo Clinic

Observational

212

Las Palmas, Madrid

2024-12-04

Active, closed

Nipocalimab in Moderate to Severe Sjogren's Disease

NCT06741969Sjogrens Syndrome

DrugNipocalimab

Janssen Research & Development, LLC

Phase 3

655

Barcelona, Huelva, Madrid, Pamplona, Santander, Seville

2024-12-04

Active, closed

A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab

NCT06706817Chronic Rhinosinusitis With Nasal Polyps

AstraZeneca

Phase 3

181

Barcelona, Cadiz, Madrid, Salamanca, Santiago de Compostela

2024-12-03

Recruiting

Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation

NCT06465953Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS), Myelodysplastic Syndromes (MDS)

DrugsIvosidenib·Azacitidine

Institut de Recherches Internationales Servier

Phase 3

Badalona, Barcelona, Madrid, Pamplona, Salamanca, Seville, Valencia

2024-12-03

Recruiting

Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic Progression

NCT06180356Ovarian Cancer, Oligometastatic Disease, Serous Ovarian Tumor

DrugNiraparib

MedSIR

Phase 2

A Coruña, Barakaldo, Barcelona, Girona, Jaén, Madrid, Málaga, Oviedo

2024-12-03

By invitation

A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

NCT06679946Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

DrugVutrisiran

Alnylam Pharmaceuticals

Phase 3

700

Barcelona, Bilbao, L'Hospitalet de Llobregat, Madrid, Málaga

2024-12-03

Active, closed

A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA)

NCT06706622Multiple System Atrophy

DrugAmlenetug

H. Lundbeck A/S

Phase 3

401

Barcelona, Barcelona (Spain), Madrid, Seville, Valencia

2024-12-03

Active, closed

Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS)

NCT06617429Angelman Syndrome

DrugApazunersen

Ultragenyx Pharmaceutical Inc

Phase 3

129

Barcelona, Madrid, Seville

2024-12-03

Recruiting

A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease

NCT06717698Chronic Kidney Disease

DrugSemaglutide

Novo Nordisk A/S

Phase 2

465

Barcelona, Córdoba, Getafe, L'Hospitalet de Llobregat, Madrid, Seville, Valencia

2024-12-02

Recruiting

A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)

NCT06667700Coronavirus Disease (COVID-19)

DrugMolnupiravir

Merck Sharp & Dohme LLC

Phase 3

3,082

Elche, Badalona, Centelles, Barcelona, A Coruña, Cartagena, Madrid, Seville

2024-12-02

Active, closed

A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1

NCT06694805HIV Infections

DrugsRpv La·B/F/TAF·Cabotegravir

ViiV Healthcare

Phase 3

326

L'Hospitalet de Llobregat, Bilbao, Puerto Real, Barcelona, Córdoba, Madrid, Málaga, Murcia

2024-12-02

Recruiting

Comparative of Sequential Application of Pulsed Dye Laser and Potassium-titanyl-phosphate Laser Treatment for Capillary Malformations Versus Single Application

NCT07015073Port-Wine Stains (Capillary Malformations)

Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal

Not applicable

Madrid

2024-12-01

Not yet open

Growing up With the Young Endocrine Support System (YESS!)

NCT04252001Congenital Adrenal Hyperplasia, Hypogonadotropic Hypogonadism, Growth Hormone Deficiency, Combined Pituitary Hormone Deficiency

dr. Laura C. G. de Graaff-Herder

Not applicable

160

Madrid

2024-12-01

By invitation

Enhancing Scleral Lens Fit With Advanced Imaging

NCT06751615Keratoconus, Astigmatism High

Fernando Fernandez Velazquez

Observational

Madrid

2024-12-01

Not yet open

Lay User Evaluation of the Panbio™ HCV Self Test in an EU Population

NCT06492018Hepatitis C

Abbott Rapid Dx

Observational

150

Madrid

2024-12-01

Recruiting

Evaluation of Clinical Impact of the Type of Cardioplegia Used in the Patient Undergoing Major Cardiac Surgery.

NCT06530641Cardiac Surgery, Cardioplegia, Heart Arrest

Lourdes Montero Cruces

Phase 4

600

Madrid

2024-12-01

Recruiting

Genetic Characterization of Patients With Arrhythmia-Induced Cardiomyopathy

NCT06896266Arrhythmia, Cardiomyopathy, Arrhythmia-induced Cardiomyopathy (AiCM)

Hospital Universitario 12 de Octubre

Observational

109

Ciudad Real, Madrid, Albacete

2024-12-01

Recruiting

Artificial Intelligence Satisfaction in Professionals and Patients

NCT06726447General Health Status

Universidad Autonoma de Madrid

Not applicable

148

Barcelona, Madrid

2024-12-01

Not yet open

Sasanlimab As Maintenance Treatment Based on Clinical Response to Neoadjuvant Treatment in Molecularly Categorized Muscle Invasive Bladder Cancer Patients

NCT06623162Mibc, Muscle Invasive Bladder Cancer

DrugsCisplatine·Gemcitabine

Fundación de investigación HM

Phase 2

Madrid

2024-12

Recruiting

Genitourinary Syndrome of Menopause in Breast Cancer

NCT06721936Genitourinary Syndrome of Menopause (GSM), Breast Cancer Female

University of Alcala

Not applicable

182

Madrid

2024-11-29

Recruiting

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC

NCT06627647Non-squamous Non-small Cell Lung Cancer

DrugsRilvegostomig·Pemetrexed·Keytruda·Cisplatin

AstraZeneca

Phase 3

1,160

Barcelona, Castellon, Las Palmas de Gran Canaria, Madrid, Majadahonda, Seville

2024-11-27

Recruiting

Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL

NCT06526793B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL)

DrugSurovatamig

AstraZeneca

Phase 2

270

Barcelona, Madrid, Pozuelo de Alarcón

2024-11-27

Active, closed

DETECTion of the Prevalence of Silent Atherosclerosis Across Adult Life - Phase I of REACT

NCT06692127Atherosclerosis, Subclinical Atherosclerosis, Cardiovascular Diseases

Copenhagen University Hospital, Rigshospitalet

Observational

16,808

Madrid

2024-11-27

Active, closed

Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine

NCT06543914Migraine

AbbVie

Observational

1,314

Málaga, L'Hospitalet de Llobregat, Leganés, Majadahonda, Oviedo, Seville, Barcelona, Madrid

2024-11-26

Recruiting

The Link Between Physical Activity and Brain Health in Healthy Adults

NCT07025070Alzheimer Disease, Inactivity, Preventive Therapy

Technical University of Madrid

Observational

Madrid

2024-11-25

Recruiting

A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

NCT06532006Gastroesophageal-junction Cancer, Monoclonal Antibody, Gastric Cancer, HER2-positive Gastric Cancer

DrugsHLX22·Trastuzumab·Capecitabine·Oxaliplatin

Shanghai Henlius Biotech

Phase 3

550

Barcelona, Madrid, Majadahonda, Oviedo, Seville, Valencia, Vigo

2024-11-22

Recruiting

Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies

NCT06458712Advanced Cancers (Breast, Ovarian, mCRPC, Pancreatic Ductal Adenocarcinoma (PDAC), Brain Mets) With Specific Mutations (Homologous Recombination Deficiency)

Duke Street Bio Ltd

Phase 1

180

Logroño, Barcelona, Córdoba, Madrid, Málaga, Pamplona, Seville, Valencia

2024-11-21

Recruiting

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

NCT06617325Systemic Lupus Erythematosus

UCB Biopharma SRL

Phase 3

450

A Coruña, Badajoz, Barcelona, Castellon, Madrid, Málaga, Mérida, Sabadell

2024-11-21

Active, closed

Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1

NCT06532656HIV-1-infection

DrugLenacapavir

Gilead Sciences

Phase 2/3

Madrid

2024-11-20

Recruiting

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

NCT06692738Non-small Cell Lung Cancer

DrugsRilvegostomig·Nab-paclitaxel·Keytruda·Paclitaxel

AstraZeneca

Phase 3

1,160

Barcelona, Las Palmas de Gran Canaria, Lleida, Madrid, Majadahonda, Seville

2024-11-18

Recruiting

A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

NCT06672549Obesity, Overweight

DrugOrforglipron

Eli Lilly and Company

Phase 3

125

Barcelona, Madrid, Málaga, Sabadell, Seville, Vitoria-Gasteiz

2024-11-18

Active, closed

A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

NCT06465329Non-Small Cell Lung Cancer

DrugsMarlotamig·Cemiplimab

Regeneron Pharmaceuticals

Phase 2

120

Badalona, Santander, Las Palmas de Gran Canaria, Pamplona, Madrid, Seville, Valencia, Zaragoza

2024-11-18

Recruiting

OvS Breast: Ovarian Suppression in Breast Cancer Interventions

NCT06727487Breast Neoplasms

Universidad Pontificia Comillas

Not applicable

Madrid

2024-11-15

Active, closed

A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine

NCT06616194Migraine

DrugRimegepant

Pfizer

Phase 3

200

Barcelona, Madrid, Vigo, Seville, Valencia, Valladolid

2024-11-15

Active, closed

Study in Paediatric Patients With Atopic Dermatitis Treated With Dupilumab in Spain

NCT06415175Atopic Dermatitis

DrugDupilumab

Sanofi

Observational

143

Santiago de Compostela, Esplugues de Llobregat, Oviedo, Seville, Alicante, Barcelona, Madrid, Málaga

2024-11-14

Recruiting

A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors

NCT06619587Solid Tumor

Genentech, Inc.

Phase 1

410

Barcelona, Madrid, Málaga, Seville, Valencia

2024-11-14

Active, closed

A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia

NCT06637501Chronic Lymphocytic Leukemia

DrugsSonrotoclax·Zanubrutinib

BeOne Medicines

Phase 2

Barcelona, Gijón, Madrid

2024-11-14

Recruiting

LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

NCT06632457Metabolic Dysfunction Associated Steatohepatitis

Boehringer Ingelheim

Phase 3

1,590

A Coruña, Barcelona, Córdoba, Madrid, Majadahonda, Pontevedra, Santiago de Compostela

2024-11-12

Active, closed

A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)

NCT06719141Developmental and Epileptic Encephalopathy

DrugBexicaserin

Longboard Pharmaceuticals

Phase 3

367

Esplugues de Llobregat, Pamplona, Barcelona, Madrid, Málaga, Valencia

2024-11-11

Not yet open

Electrolysis in Patients With Chronic Plantar Fasciitis

NCT06674902Plantar Fasciitis

Wroclaw University of Health and Sport Sciences

Not applicable

Madrid

2024-11-11

Active, closed

A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)

NCT06537414Chronic Hepatitis B Virus Infection, Hepatitis B

DrugBepirovirsen

GlaxoSmithKline

Phase 2

283

Barcelona, León, Madrid, Salamanca, Santander, Valencia

2024-11-11

Recruiting

Closed-blood Sampling Devices in the Adult Critically Ill Patient

NCT06478160Acceptability of Health Care

University of Barcelona

Not applicable

216

Madrid, Seville

2024-11-11

Active, closed

A Study on Safety and Effectiveness of Long-term Treatment With Vamorolone in Boys With Duchenne Muscular Dystrophy

NCT06713135Duchenne Muscular Dystrophy

DrugVamorolone

Santhera Pharmaceuticals

Phase 4

Madrid, Valencia

2024-11-10

Recruiting

Study of IMC-P115C in Advanced PRAME-Positive Cancers

NCT07156136PRAME Positive, Cancer, HLA-A*02:01-positive

Immunocore Ltd

Phase 1

140

Barcelona, Madrid

2024-11-07

Active, closed

Abbott Medical - VERITAS Study

NCT06707688Atrial Fibrillation (AF), Stoke

Abbott Medical Devices

Not applicable

458

Barcelona, Madrid, Salamanca

2024-11-07

Active, closed

Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma

NCT06676319Asthma

DrugsBudesonide/Formoterol·Lunsekimig

Sanofi

Phase 2

556

Santiago de Compostela, Badalona, Santander, Barcelona, Madrid, Benalmádena, Girona, Málaga

2024-11-07

Active, closed

Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants

NCT06647407Meningococcal Immunization, Healthy Volunteers

DrugsMenACYW conjugate vaccine·Nimenrix·Vaxelis vaccine·Bexsero

Sanofi Pasteur, a Sanofi Company

Phase 1/2

750

Seville, Madrid

2024-11-05

Recruiting

A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa

NCT06298565Myasthenia Gravis

DrugEfgartigimod

argenx

Observational

680

Barcelona, Madrid, Seville

2024-11-04

Not yet open

Electrolysis in Patients With Low Back Pain

NCT06661070Low Back Pain

Wroclaw University of Health and Sport Sciences

Not applicable

Madrid

2024-11-04

Not yet open

Impact on Quality of Life and Burden of Disease in Adults With Herpes Zoster

NCT06667245Herpes Zoster, Quality of Life, Immunization; Infection

Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz

Observational

357

Madrid

2024-11-04

Active, closed

Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)

NCT06596694Gastrointestinal Cancer

DrugPatritumab deruxtecan

Merck Sharp & Dohme LLC

Phase 1/2

180

Oviedo, Barcelona, Madrid

2024-11-03

Recruiting

Wide-Antral Pulmonary Vein Isolation in Atrial Fibrillation Ablation with a Single-shot Technique (WIDER-PVI)

NCT06698159Atrial Fibrillation, Atrial Fibrillation (Paroxysmal)

Hospital Universitario 12 de Octubre

Not applicable

440

Bilbao, Granada, Huelva, Madrid, Málaga, Seville

2024-11-01

Recruiting

Effects of Walking Apnea At High Lung Volume on Hypoalgesia

NCT06638528Pain, Hypoxemia, Hypercapnia, Apnea

Universidad Rey Juan Carlos

Not applicable

Madrid

2024-11-01

Recruiting

Effects of Walking Apnea At Low Lung Volume on Hypoalgesia

NCT06638515Pain, Hypoxemia, Hypercapnia, Apneas

Universidad Rey Juan Carlos

Not applicable

Madrid

2024-11-01

Active, closed

A Study of ZW191 in Participants With Solid Tumors

NCT06555744Advanced Solid Tumors

Zymeworks BC Inc.

Phase 1

145

Barcelona, Córdoba, Madrid, Valencia

2024-10-30

Recruiting

A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma

NCT06630806Plasma Cell Myeloma Refractory

Sanofi

Phase 1

Barcelona, Madrid

2024-10-30

Recruiting

Study of Tacrolimus Melt-Dose® for Lung Transplant Patients

NCT07042035Lung Trasplant, Lung Transplantation

Chiesi España, S.A.U.

Observational

240

L'Hospitalet de Llobregat, Madrid

2024-10-29

Active, closed

A Study of Mosliciguat in PH-ILD

NCT06635850Pulmonary Hypertension, Interstitial Lung Disease, Lung Diseases, Vascular Diseases

DrugMosliciguat

Pulmovant, Inc.

Phase 2

135

Santander, Marbella, Madrid, Toledo

2024-10-29

Recruiting

International Pilot Study for Dual Non-invasive Assesment of Embryo Development

NCT06524648Infertility

Igenomix

Observational

200

Barcelona, Madrid, Murcia, Seville, Valencia

2024-10-29

Active, closed

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis

NCT06655896Scleroderma, Diffuse

DrugsRapcabtagene autoleucel·Rituximab

Novartis Pharmaceuticals

Phase 2

Santiago Compostela, Santander, Pamplona, Barcelona, Córdoba, Madrid, Málaga, Salamanca

2024-10-29

Recruiting

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

NCT06625775Solid Tumor, Adult, Metastatic Breast Cancer, Advanced Breast Cancer, HER2 Mutation-Related Tumors

DrugsBBO-10203·Ribociclib·Folfox·Fulvestrant

TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

Phase 1

392

Barcelona, Madrid, Pozuelo de Alarcón, Lleida, Valencia

2024-10-29

Active, closed

A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy

NCT06413706Glioma

DrugsAbemaciclib·Temozolomide

Eli Lilly and Company

Phase 2

Barcelona, Córdoba, Esplugues de Llobregat, Madrid, Seville, Valencia

2024-10-25

Recruiting

A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

NCT06638307Advanced Breast Cancer

DrugElacestrant

Stemline Therapeutics, Inc.

Phase 1

240

Barcelona, Madrid, Valencia

2024-10-25

Active, closed

Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)

NCT06602193Parkinson Disease

Denali Therapeutics Inc.

Phase 2

Barcelona, Donostia / San Sebastian, Madrid, Santander, Seville

2024-10-24

Recruiting

Study of JK06 in Patients With Unresectable Locally Advanced or Metastatic Cancer

NCT06667960Solid Tumor

Salubris Biotherapeutics Inc

Phase 1/2

255

Barcelona, Madrid, Pamplona, Rioja, Valencia

2024-10-23

Recruiting

Gelsectan® in the Treatment of Patients With Diarrhoea-predominant Irritable Bowel Syndrome

NCT06681012Irritable Bowel Syndrome (IBS), Irritable Bowel Syndrome of Diarrhea Type (IBS-D)

Devintec Sagl

Not applicable

330

Barcelona, Madrid

2024-10-22

Recruiting

FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations

NCT06669117Solid Tumor, MET Alteration

Pierre Fabre Medicament

Phase 1/2

140

Madrid

2024-10-22

Recruiting

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

NCT06629779Metastatic Castration-Resistant Prostate Cancer

DrugsMevrometostat·Xtandi·Enzalutamide

Pfizer

Phase 3

900

L'Hospitalet de Llobregat, Madrid, Valencia

2024-10-22

Active, closed

A Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R B-Cell NHL)

NCT06660563Lymphoma, Non-Hodgkin

DrugsJNJ-75348780·JNJ-80948543

Janssen Research & Development, LLC

Phase 1

Barcelona, L'Hospitalet de Llobregat, Madrid

2024-10-22

Active, closed

Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of Age With AAV.

NCT06321601Vasculitis

DrugAvacopan

Amgen

Phase 3

Barcelona, Esplugues de Llobregat, Madrid

2024-10-22

Recruiting

The Sagittarius Trial

NCT06490536Colon Cancer Stage II, Colon Cancer Stage III

DrugsFolinic acid·Panitumumab·Pertuzumab·Temozolomide

IFOM ETS - The AIRC Institute of Molecular Oncology

Phase 3

700

Barcelona, Valencia, Córdoba, Madrid, Pamplona, Santander, Santiago de Compostela, Zaragoza

2024-10-22

Active, closed

A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).

NCT06551324Metastatic Castrate Resistant Prostate Cancer (mCRPC)

DrugsMevrometostat·Xtandi·Taxotere·Enzalutamide

Pfizer

Phase 3

600

L'Hospitalet de Llobregat, Barcelona, Madrid, Manresa, Valencia

2024-10-21

Recruiting

Gastric POCUS for Airway Management in Patients Using Glucagon-like Peptide-1 Receptor Agonist (Multicentric)

NCT06666049Aspiration Pneumonia

Clinica Universidad de Navarra, Universidad de Navarra

Observational

Madrid, Salamanca

2024-10-21

Recruiting

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

NCT06623422Carcinoma, Non-Small-Cell Lung

DrugsIntismeran autogene·Paraplatin·Taxol·Pemetrexed

Merck Sharp & Dohme LLC

Phase 3

680

Canarias, A Coruña, Pozuelo de Alarcón, Barcelona, Madrid, Málaga

2024-10-21

Active, closed

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

NCT06607185Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor

Drugs5Fluorouracil·Leucovorin·Irinotecan·Cetuximab

Eli Lilly and Company

Phase 1

750

Barcelona, Madrid, Málaga

2024-10-21

Recruiting

A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia

NCT06544499Primary Immune Thrombocytopenia (ITP)

DrugEfgartigimod

argenx

Phase 3

A Coruña, L'Hospitalet de Llobregat, Madrid, Murcia, Pozuelo de Alarcón, Valencia

2024-10-18

Active, closed

Short-term Interruption Versus Continuous Anticoagulation in Colorectal Polypectomy

NCT07185295Anticoagulated Patients

Outcomes'10

Phase 4

481

Palma, Torrelavega, Valladolid, Barcelona, Alcalá de Henares, Madrid, Majadahonda, Avilés

2024-10-18

Recruiting

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

NCT06662786Colorectal Neoplasms

DrugsLeucovorin calcium/Levoleucovorin·Amivantamab·Erbitux·Irinotecan

Janssen Research & Development, LLC

Phase 3

1,000

Barcelona, Madrid, Pamplona, Seville, Valencia

2024-10-18

Active, closed

Evaluation of Efficacy and Safety of Oral Minoxidil 1 mg in Female Androgenetic Alopecia

NCT05888922Androgenetic Alopecia, Female Pattern Baldness

DrugMinoxidil

Industrial Farmacéutica Cantabria, S.A.

Phase 3

520

Barcelona, Madrid, Valencia

2024-10-17

Active, closed

Randomized Double-Blind Trial on Safety and Efficacy of Nanordica Advanced Antibacterial Wound Dressing for Diabetic Foot Ulcer

NCT06667752Diabetic Foot Ulcer, Diabetic Foot Infection

Nanordica Medical OU

Not applicable

136

Arcos de la Frontera, Cadiz, Jerez de la Frontera, León, Madrid, San Sebastián

2024-10-17

Active, closed

Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

NCT06625320Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma

DrugsLiposomal Irinotecan·Leucovorin·Irinotecan·Cetuximab

Revolution Medicines, Inc.

Phase 3

500

Barcelona, Madrid, Pamplona, Valencia

2024-10-16

Active, closed

A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults With Eosinophilic Esophagitis

NCT06598462Eosinophilic Esophagitis (EoE)

DrugSolrikitug

Uniquity One (UNI)

Phase 2

184

Barcelona, Madrid, Tomelloso

2024-10-16

Recruiting

Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

NCT06562192Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer

Novartis Pharmaceuticals

Phase 1

162

Barcelona, Madrid

2024-10-15

Active, closed

Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response

NCT06641089Arthritis, Psoriatic

DrugsSonelokimab·Risankizumab

MoonLake Immunotherapeutics AG

Phase 3

600

A Coruña, Alcobendas, Bilbao, Castellon, Madrid, Málaga, Sabadell, Santiago de Compostela

2024-10-15

Active, closed

RTX001 Autologous Engineered Macrophages for Liver Cirrhosis

NCT06823713End-stage Liver Disease (ESLD), Cirrhosis, Liver, Cirrhosis, Decompensated, Liver Diseases

Resolution Therapeutics Limited

Phase 1/2

Barcelona, Córdoba, Madrid, Seville, Valencia

2024-10-15

Recruiting

A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers

NCT06663319Colorectal Neoplasms, Gastrointestinal Neoplasms

DrugsFolfox·Bevacizumab

Janssen Research & Development, LLC

Phase 1

260

Barcelona, Madrid

2024-10-15

Active, closed

Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug

NCT06641076Arthritis, Psoriatic

DrugSonelokimab

MoonLake Immunotherapeutics AG

Phase 3

960

A Coruña, Alcobendas, Bilbao, Castelló, Madrid, Málaga, Sabadell, Santiago de Compostela

2024-10-15

Recruiting

Clinical Epidemiology in Contemporary Patients With Myelofibrosis.

NCT06533813Myelofibrosis

FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS

Observational

617

Barcelona, Madrid

2024-10-14

Recruiting

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

NCT06632444Metabolic Dysfunction Associated Steatohepatitis (MASH), Liver Fibrosis

Boehringer Ingelheim

Phase 3

1,800

A Coruña, Barcelona, Córdoba, Madrid, Majadahonda, Pontevedra, Santander, Santiago de Compostela

2024-10-14

Active, closed

A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment

NCT06447168Primary Biliary Cholangitis

Ipsen

Observational

424

Almería, Barcelona, Madrid, Pontevedra, Santander

2024-10-14

Active, closed

A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65)

NCT06504394Classical Hodgkin Lymphoma Recurrent, Classical Hodgkin Lymphoma Refractory, Primary Mediastinal Large B-cell Lymphoma Recurrent, Primary Mediastinal Large B-cell Lymphoma Refractory

Drugs) Berahyaluronidase alfa·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 2

L'Hospitalet Del Llobregat, Salamanca, Madrid

2024-10-14

Active, closed

Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)

NCT06553768Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)

DrugMaralixibat

Mirum Pharmaceuticals, Inc.

Phase 3

Barcelona, Madrid

2024-10-14

Recruiting

A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy

NCT05460000Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Clear Cell Carcinoma

North Eastern German Society of Gynaecological Oncology

Phase 2

640

Alicante, Granada, Lugo, Madrid, Manresa, Seville, Tarragona, Valencia

2024-10-11

Recruiting

Diagnostic HER2DX-guided Treatment for Patients wIth Early-stage HER2-positive Breast Cancer

NCT06446882HER2-positive Breast Cancer, Early-stage Breast Cancer

Fundacio Clinic Barcelona

Not applicable

304

L'Hospitalet de Llobregat, Granada, Santiago de Compostela, León, Madrid, Murcia, Reus, Bilbao

2024-10-11

Active, closed

A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease

NCT06388564Chronic Graft-versus-host-disease

DrugsAxatilimab·Ruxolitinib·Methylprednisolone·Prednisolone

Incyte Corporation

Phase 2

130

Barcelona, El Palmar, Granada, Granvia de L'hospitalet 199-203, Madrid, Málaga, Salamanca, Santander

2024-10-11

Recruiting

Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations

NCT06581432Solid Tumours

DrugZongertinib

Boehringer Ingelheim

Phase 2

588

A Coruña, Badalona, Barcelona, Madrid, Pamplona, Seville, Valencia

2024-10-11

Active, closed

Efficacy of Focused Shock Wave Therapy Before and After Botulinum Toxin Injection in Patients With Post-Stroke Spastic Equinus/Equinovarus Foot: A Randomized Clinical Trial

NCT07758322Post-Stroke Spasticity, Spastic Equinovarus Foot

DrugsOnabotulinumtoxinA·Botulinum toxin type A

María Belén Martínez Luna

Not applicable

Madrid

2024-10-10

Active, closed

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)

NCT06516965Prurigo Nodularis

DrugPovorcitinib

Incyte Corporation

Phase 3

346

Alicante, Badalona, Barcelona, Córdoba, Granada, Madrid, Majadahonda, Manises

2024-10-10

Active, closed

A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults

NCT06625060Episodic Migraine, Chronic Migraine

DrugCorabotase

Ipsen

Phase 2

670

Barcelona, Cadiz, Madrid, Santander, Seville, Valladolid

2024-10-10

Active, closed

A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

NCT06598943Ulcerative Colitis, Ulcerative Colitis Chronic

DrugMirikizumab

Eli Lilly and Company

Phase 2

143

Barcelona, Ciudad Real, Córdoba, Huelva, Las Palmas de GC, Madrid, Santiago de Compostela, Seville

2024-10-10

Recruiting

A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia

NCT06525636X-linked Hypophosphatemia

Kyowa Kirin Co., Ltd.

Phase 1/2

Madrid

2024-10-09

Recruiting

Ampicillin and Ceftriaxone for the Treatment of Enterococcus Faecalis Infective Endocarditis.

NCT06423898Endocarditis, Infective

DrugAmpicillin

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

Phase 4

284

Alava, Barakaldo, Barcelona, Donostia / San Sebastian, Granada, Logroño, Madrid, Málaga

2024-10-09

Recruiting

A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis

NCT06470048Diffuse Cutaneous Systemic Sclerosis

DrugIanalumab

Novartis Pharmaceuticals

Phase 2

200

Málaga, Valencia, Barcelona, Madrid, Salamanca

2024-10-09

Active, closed

Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1

NCT06630299HIV-1-Infection

DrugsAntiretroviral Combinations·ISL/LEN

Gilead Sciences

Phase 3

600

Barcelona, Madrid, Seville

2024-10-08

Active, closed

An Ascending Dose Study of PIT565 in Participants With Systemic Lupus Erythematosus (SLE).

NCT06335979Systemic Lupus Erythematosus, SLE

DrugPIT565

Novartis Pharmaceuticals

Phase 1

Santiago Compostela, Barcelona, Madrid

2024-10-08

Recruiting

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

NCT06561386Non-small Cell Lung Cancer

DrugsRelatlimab·Pemetrexed·Nivolumab·Cisplatin

Bristol-Myers Squibb

Phase 3

1,000

A Coruña, Barcelona, L'Hospitalet de Llobregat, Palma, Madrid, Majadahonda, Valencia, Málaga

2024-10-07

Recruiting

A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine

NCT06602479Migraine

AbbVie

Phase 2

488

Badajoz, Barcelona, Madrid, Valencia

2024-10-07

Active, closed

Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Anti-PD-1/PD-L1 Therapy in Patients With Solid Tumors

NCT06631079Solid Tumor

NEC Bio B.V

Phase 1/2

Barcelona, Madrid, Santiago de Compostela

2024-10-07

Recruiting

Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)

NCT06598306Extensive Stage Small Cell Lung Cancer

DrugTarlatamab

Amgen

Phase 1

220

Málaga, Barcelona, Valencia, Madrid

2024-10-07

Recruiting

Efficacy of INM004 in Children With STEC-HUS

NCT06389474Hemolytic-Uremic Syndrome

Inmunova S.A.

Phase 3

220

Barakaldo, Madrid

2024-10-05

Recruiting

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT06417814Metastatic Non-small Cell Lung Cancer

DrugsTagrisso·Dato-DXd·Osimertinib·Pemetrexed

AstraZeneca

Phase 3

744

A Coruña, Barakaldo, Barcelona, El Palmar, L'Hospitalet de Llobregat, Madrid, Majadahonda, Málaga

2024-10-04

Recruiting

Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)

NCT05947955Acute Respiratory Distress Syndrome, Infections

BioAegis Therapeutics Inc.

Phase 2

600

Barcelona, Madrid, Tarragona

2024-10-03

Recruiting

A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)

NCT06343805Primary Myelofibrosis

Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company

Phase 1

256

Barcelona, Madrid

2024-10-03

Active, closed

A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy

NCT06568237Multiple System Atrophy

DrugEmrusolmin

Teva Branded Pharmaceutical Products R&D LLC

Phase 2

349

Barakaldo, Barcelona, Elche, Madrid, Pamplona, Seville, Valencia

2024-10-02

Recruiting

Association of Assisted Reproductive Technologies Parameters With the Perinatal Outcome

NCT06918236Fetal Growth Restriction (FGR), Preeclampsia, Stillbirth, Placenta Previa

Aristotle University Of Thessaloniki

Observational

12,084

Santa Cruz de Tenerife, Madrid, Murcia

2024-10-01

Recruiting

Automated Passive Case-Finding for Advanced Liver Fibrosis in MASLD: The LiverSeek Programme

NCT07658755Metabolic Dysfunction-Associated Steatotic Liver Disease, Liver Fibrosis, Non-alcoholic Fatty Liver Disease NAFLD, Type 2 Diabetes Mellitus

Hospital General Universitario Gregorio Marañon

Observational

3,000

Madrid

2024-10-01

Not yet open

Clinical and Endoscopic Characterization of Patients With Multiple Colorectal Adenomas: A Multicenter Study in Spain (ESPAPOLYP Study)

NCT06625788Colorectal Cancer Control and Prevention

Asociación Española de Gastroenterología

Observational

200

Madrid

2024-10-01

Recruiting

A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer

NCT06545955Non-muscle Invasive Bladder Cancer With Carcinoma in Situ

DrugsNadofaragene Firadenovec·Docetaxel·Gemcitabine·Pembrolizumab

Ferring Pharmaceuticals

Phase 3

250

Santander, Barcelona, Córdoba, A Coruña, Alcorcón, Madrid, Pamplona, Bilbao

2024-10-01

Recruiting

Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer

NCT06510374Intermediate Risk Non-Muscle Invasive Bladder Cancer

DrugNadofaragene Firadenovec

Ferring Pharmaceuticals

Phase 3

454

Santander, Barcelona, Córdoba, A Coruña, Granada, Alcorcón, Madrid, Bilbao

2024-10-01

Active, closed

Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.

NCT06506955Advanced/Metastatic Cancer

DrugFutibatinib

Taiho Oncology, Inc.

Phase 2/3

Barcelona, Madrid

2024-10-01

Recruiting

Atrial Fibrillation Ablation Versus Atrioventricular Nodal Ablation with Conduction System Pacing in Heart Failure

NCT06207383Atrial Fibrillation, Persistent, Heart Failure

University Hospital, Geneva

Not applicable

220

Madrid

2024-10-01

Recruiting

Multicenter Trial of Proximal Femoral Guided Growth in Children With CP and Hips at Risk of Dislocation (GGSH-MC)

NCT06956729Cerebral Palsy

Fundación para la investigación biomética Hospital Infantil Universitario Niño Jesús

Not applicable

A Coruña, Almería, Seville, Palma, Salamanca, Barcelona, Donostia / San Sebastian, Madrid

2024-10-01

Recruiting

Real World European Investigation of Safety and Clinical Efficacy of the EVOQUE System (TRISCEND III EU)

NCT06569602Tricuspid Valve Regurgitation, Heart Valve Diseases, Cardiovascular Diseases

Edwards Lifesciences

Observational

500

Madrid

2024-10-01

Active, closed

Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.

NCT06473779Severe Asthma

AstraZeneca

Phase 3

310

Badalona(Barcelona), Barcelona, Lugo, Madrid

2024-09-30

By invitation

Open-Label Extension Study to Assess GLM101 in PMM2-CDG Patients

NCT06657859Pmm2-CDG, Phosphomannomutase 2 Deficiency

Glycomine, Inc.

Phase 2

Esplugues de Llobregat, Madrid

2024-09-30

By invitation

Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma

NCT06609239Asthma

DrugLunsekimig

Sanofi

Phase 2

900

Barcelona, Madrid

2024-09-30

Recruiting

A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)

NCT06551142Neoplasms

DrugsRis-Rez·Tarlatamab·Dostarlimab·Cetuximab

GlaxoSmithKline

Phase 1

845

Badajoz, Barcelona, Madrid, Málaga, Valencia, Zaragoza

2024-09-30

Recruiting

First-in-human Trial of EGL-001 in Patients with Selected Advanced And/or Metastatic Solid Tumors

NCT06622486Solid Tumor, Adult

Egle Therapeutics

Phase 1/2

Barcelona, Madrid, Pamplona, Valencia

2024-09-27

Recruiting

A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease

NCT06613698Liver Diseases, Alcoholic

DrugGSK4532990

GlaxoSmithKline

Phase 2

393

Barcelona, León, Madrid, Santander, Seville, Valencia, Valladolid, Vigo

2024-09-27

Recruiting

A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

NCT06585787Alzheimer Disease

DrugKarXT

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

406

Majadahonda, Málaga, Lleida, Madrid, Salamanca, Seville, Valladolid, Zaragoza

2024-09-26

Recruiting

A Study to Learn About the Study Medicine Aztreonam-Avibactam (ATM-AVI) in Infants and Newborns Admitted in Hospitals With Bacterial Infection (CHERISH)

NCT06462235Gram-negative Bacterial Infection

Pfizer

Phase 2

Madrid

2024-09-25

Active, closed

A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)

NCT06660394Dravet Syndrome

DrugBexicaserin

Longboard Pharmaceuticals

Phase 3

Esplugues de Llobregat, Pamplona, Barcelona, Madrid, Málaga

2024-09-25

Active, closed

A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

NCT06525220Head and Neck Squamous Cell Carcinoma

DrugsPetosemtamab·Pembrolizumab

Merus B.V.

Phase 3

699

Badalona, Barcelona, Madrid, Marbella, Pamplona, Valencia

2024-09-25

Recruiting

Trial of THEO-260 in Ovarian Cancer Patients

NCT06618235Ovarian Cancer

DrugTHEO-260

Theolytics Limited

Phase 1/2

Madrid

2024-09-24

Active, closed

A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer

NCT06497556Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer

DrugsDivarasib·Adagrasib·Sotorasib

Hoffmann-La Roche

Phase 3

338

L'Hospitalet de Llobregat, Seville, Barcelona, Madrid, Málaga, Valencia, Zaragoza

2024-09-23

Active, closed

To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications

NCT06553027Parkinson Disease

Cerevance

Phase 3

330

Seville, Sant Cugat del Vallès, Barakaldo, San Sebastián, Valencia, Barcelona, Madrid

2024-09-20

Active, closed

A Study to Investigate Safety of INT2104 Infusions in Participants Aged 18 Years of Age and Older Who Have B-cell Cancers That Came Back After Previous Treatment

NCT06539338Lymphomas Non-Hodgkin's B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Kite, A Gilead Company

Phase 1

Madrid

2024-09-20

Recruiting

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

NCT06561685Metastatic Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, SMARCA4-Deficient Tumor

DrugsNab-paclitaxel·Pemetrexed·Paclitaxel·Cisplatin

Eli Lilly and Company

Phase 1

340

Barcelona, Madrid

2024-09-19

Recruiting

A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

NCT06635148Geographic Atrophy, Macular Degeneration

Janssen Research & Development, LLC

Phase 2/3

274

Barcelona, Burjassot, Córdoba, Madrid, Majadahonda, Pamplona, Sant Cugat del Vallès, Seville

2024-09-19

Active, closed

A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma

NCT06190951Melanoma

DrugsFianlimab·Cemiplimab

Regeneron Pharmaceuticals

Phase 2

151

Granada, Málaga, Palma, Badalona, Barcelona, El Palmar, Oviedo, Madrid

2024-09-18

Active, closed

A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis

NCT06558279Myasthenia Gravis, Ocular

argenx

Phase 3

141

Barcelona, Madrid, San Sebastián, Valencia

2024-09-18

Recruiting

A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

NCT06542250B-cell Malignancies

DrugAZD5492

AstraZeneca

Phase 1/2

174

Barcelona, L'Hospitalet de Llobregat, Madrid

2024-09-18

Active, closed

Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).

NCT06333951Thoracic Tumors, Non-small Cell Lung Cancer

DrugsAnvumetostat·Sotorasib·Pemetrexed·Paclitaxel

Amgen

Phase 1

Barcelona, Madrid

2024-09-17

Active, closed

A Study of Obexelimab in Patients With Systemic Lupus Erythematosus

NCT06559163Systemic Lupus Erythematosus

DrugObexelimab

Zenas BioPharma (USA), LLC

Phase 2

190

Barcelona, Madrid, Seville

2024-09-17

Recruiting

Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs

NCT06567015Non-small Cell Lung Cancer (NSCLC)

Pierre Fabre Medicament

Phase 1/2

171

Barcelona, Logroño, Madrid

2024-09-17

Active, closed

Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)

NCT06497504Hepatitis B

DrugBepirovirsen

GlaxoSmithKline

Phase 2

153

Barcelona, Córdoba, Madrid

2024-09-17

Recruiting

European Registry of Next Generation Imaging in Advanced Prostate Cancer

NCT06866782Prostate Cancer, Advanced Prostate Cancer, Metastatic Prostate Cancer (mPC)

Fundacio Puigvert

Observational

600

Barcelona, Córdoba, Madrid, San Cristóbal de La Laguna, Santander, Santiago de Compostela

2024-09-17

Active, closed

A Dose-escalation Study of RO7567132 as Single Agent and in Combination With Atezolizumab in Participants With Advanced Solid Tumors

NCT06537310Cancer-Neoplasms

Hoffmann-La Roche

Phase 1

Pamplona, Barcelona, Madrid

2024-09-16

Recruiting

A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma

NCT06140524Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM)

DrugLinvoseltamab

Regeneron Pharmaceuticals

Phase 2

116

Granada, Terrassa, El Palmar, Gijón, Barcelona, Madrid, Murcia

2024-09-16

Recruiting

Sacituzumab govitEcan in THYroid Cancers

NCT06235216Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer

DrugSacituzumab Govitecan

Grupo Espanol de Tumores Neuroendocrinos

Phase 2

Barcelona, Ferrol, Hospitalet de Llobregat (Barcelona), Madrid, Murcia, Oviedo, Santander, Zaragoza

2024-09-13

Recruiting

MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

NCT06586515Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer

DrugsLeucovorin·Irinotecan·Cetuximab·Adrucil

Eli Lilly and Company

Phase 1

630

Barcelona, Madrid

2024-09-12

Active, closed

Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)

NCT06430866Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)

DrugsABP 234·Pembrolizumab

Amgen

Phase 3

163

A Coruna Galicia, A Coruña, Alicante, Badalona, Barcelona, Jerez de la Frontera, Madrid, Mataró

2024-09-12

Active, closed

A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis

NCT06431373Uveitis, Posterior, Uveitis, Intermediate, Uveitis

Priovant Therapeutics, Inc.

Phase 3

371

Barcelona, Madrid, Valladolid

2024-09-11

Recruiting

A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis

NCT06559150Non-cystic Fibrosis Bronchiectasis

Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA

Phase 2

284

A Coruña, Barcelona, Madrid

2024-09-11

Recruiting

A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease

NCT06572384Lung Diseases, Interstitial

DrugBelimumab

GlaxoSmithKline

Phase 3

440

Pamplona Iruna, Barcelona, Córdoba, Granada, Madrid, Málaga, Santander, Seville

2024-09-11

Recruiting

A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B

NCT06379789Hemophilia B

Regeneron Pharmaceuticals

Phase 1/2

130

Seville, A Coruña, El Palmar, Oviedo, Barcelona, Madrid, Valencia, Zaragoza

2024-09-11

Active, closed

Efficacy and Safety of Gemlapodect (NOE-105) in Adults and Adolescents With Tourette Syndrome

NCT06315751Tourette Syndrome

Noema Pharma AG

Phase 2

164

Barcelona, Burgos, Madrid, Oviedo, Sant Cugat del Vallès, Seville

2024-09-10

Active, closed

RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms

NCT06243458Low Risk Myelodysplastic Syndromes

DrugRVU120

GCP-Service International West GmbH

Phase 2

Barcelona, León, Madrid, Pamplona, Salamanca, Valencia

2024-09-10

Recruiting

Safety and Effectiveness of Mechanical Thrombectomy Using the Anaconda ANA Funnel Catheter

NCT06370182Acute Ischemic Stroke From Large Vessel Occlusion

Anaconda Biomed S.L.

Not applicable

327

Barcelona, Madrid, Murcia, Oviedo

2024-09-09

Active, closed

A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

NCT06311721Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

DrugsABP 234·Keytruda·Pembrolizumab

Amgen

Phase 3

315

Alicante, Barcelona, Jaén, Madrid, Mataró, Málaga, Oviedo, Seville

2024-09-09

Recruiting

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

NCT06393738Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL), Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)

DrugGlofitamab

Arvinas Inc.

Phase 1

329

El Palmar, Pamplona, Barcelona, Madrid, Salamanca

2024-09-05

Active, closed

A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)

NCT06581198Lupus Erythematosus, Systemic, Lupus Nephritis

DrugRapcabtagene autoleucel

Novartis Pharmaceuticals

Phase 2

179

Santiago Compostela, Santander, Pamplona, Barcelona, Córdoba, Madrid, Salamanca, Valencia

2024-09-04

Recruiting

Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

NCT06548542Crohn's Disease

DrugsABBV-8736·Trosunilimab·Lutikizumab·Risankizumab

AbbVie

Phase 2

590

Santiago de Compostela, Seville, Barcelona, Madrid, Pontevedra, Valencia

2024-09-04

Recruiting

A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

NCT06528314NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis

DrugEfruxifermin

Akero Therapeutics, Inc

Phase 3

2,150

Sabadell, Santander, Majadahonda, Barcelona, Madrid, Seville, Valencia

2024-09-04

Active, closed

A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)

NCT06616974Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction

Tectonic Therapeutic

Phase 2

191

Barcelona, Madrid, Santiago de Compostela, Valencia

2024-09-04

Recruiting

ATLAS (AltaValve) Pivotal Trial

NCT06465745Mitral Regurgitation, Mitral Insufficiency, Mitral Valve Incompetence, Mitral Valve Regurgitation

4C Medical Technologies, Inc.

Not applicable

450

Barcelona, Madrid, Vigo

2024-09-03

Recruiting

Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)

NCT06274801Pulmonary Arterial Hypertension

Gossamer Bio USA, Inc.

Phase 3

330

Barcelona, Madrid, Santander, Seville, Toledo

2024-09-03

Recruiting

Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT06544785Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugsZanubrutinib Product·Zanubrutinib·Obinutuzumab

PETHEMA Foundation

Phase 2

106

Alicante, Barcelona, Córdoba, Las Palmas de Gran Canaria, Madrid, Marbella, Málaga, Oviedo

2024-09-02

Recruiting

CRS Questionnaire Validation Project

NCT06970977Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps

The European Forum for Research and Education in Allergy and Airway Diseases

Observational

1,000

A Coruña, Barcelona, Cadiz, Madrid, Ponferrada, Santander, Seville, Valencia

2024-09-01

Recruiting

Respiratory Rehabilitation Based on Eccentric Exercice on Treadmill After Thoracic Surgery

NCT06493877Thoracic Surgery, Breathing, Muscle

Universidad Europea de Madrid

Not applicable

Madrid

2024-09

Recruiting

Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host Disease

NCT06343792Steroid Refractory GVHD

DrugRLS-0071

ReAlta Life Sciences, Inc.

Phase 2

Seville, Madrid, Salamanca

2024-08-31

Recruiting

Open Label Trial Studying the Safety and Effectiveness of ILUVIEN® (190μg) in Children and Adolescents, Who Have Recurrent Non-infectious Uveitis Affecting the Posterior Segment of the Eye.

NCT06539481Non-infectious Uveitis Affecting the Posterior Segment of the Eye

Alimera Sciences

Phase 4

Bilbao, Madrid

2024-08-31

Active, closed

A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.

NCT06116136MSI-H/dMMR Gastroesophageal-junction Cancer, MSI-H/dMMR Gastric Cancer

DrugsS095029·Keytruda·Pembrolizumab

Servier Bio-Innovation LLC

Phase 1/2

Barcelona, Madrid, Santander, Valencia

2024-08-31

Active, closed

Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)

NCT06564142Immunoglobulin A Nephropathy

DrugPovetacicept

Alpine Immune Sciences Inc, A Subsidiary of Vertex

Phase 3

605

Barcelona, Córdoba, Lleida, Madrid, Pamplona, Santiago de Compostela, Seville, Valencia

2024-08-30

Active, closed

A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma

NCT06425302Lymphoma, Follicular

DrugsEndoxan·Golcadomide·Pegylated liposomal doxorubicin·Bendamustine

Celgene

Phase 2

Palma, Valencia, Madrid

2024-08-30

Active, closed

A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer

NCT06331299Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder

UroGen Pharma Ltd.

Phase 3

Málaga, Barcelona, Madrid

2024-08-29

Active, closed

A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease

NCT06557772Coeliac Disease, Celiac Disease

DrugAmlitelimab

Sanofi

Phase 2

229

Barcelona, Chiclana de la Frontera, Las Palmas de Gran Canaria, Seville, Madrid, Málaga

2024-08-29

Recruiting

A Study of the Intestinal Microbiota in Children and Adolescents With Eating Disorders. A Perspective From Psychoneuroimmunology

NCT07066033Eating Disorders in Adolescence, Eating Disorders in Children

Esther Nova

Observational

158

Madrid

2024-08-29

Active, closed

A Phase 1b Trial to Evaluate Safety of MB097 in Combination With Pembrolizumab in Melanoma Patients

NCT06540391Melanoma

DrugsVancomycin·Keytruda·Pembrolizumab

Microbiotica Ltd

Phase 1

Madrid, Valencia

2024-08-28

Recruiting

A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

NCT06452277Advanced Non-small Cell Lung Cancer, HER2 Mutation

DrugsSevabertinib·Pemetrexed·Cisplatin·Carboplatin

Bayer

Phase 3

555

Badalona, Majadahonda, Pamplona, A Coruña, Barcelona, Madrid, Valencia

2024-08-28

Active, closed

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)

NCT06486441Endometrial Cancer

DrugsAdriamycin·Sacituzumab Govitecan·Taxol·Doxorubicin

Gilead Sciences

Phase 3

640

A Coruña, Barcelona, Jaén, Madrid, Málaga, Palma, Sabadell, San Sebastián

2024-08-28

Active, closed

An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)

NCT06625411Thyroid Eye Disease

DrugVRDN-003

Viridian Therapeutics, Inc.

Phase 3

132

Santiago de Compostela, Seville, Córdoba, Madrid, Zaragoza

2024-08-27

Active, closed

Volrustomig Priming Regimens Exploratory Phase II Platform Study

NCT06448754Non-small Cell Lung Cancer

DrugsVolrustomig·Ramucirumab·Pemetrexed·Paclitaxel

AstraZeneca

Phase 2

194

A Coruña, Alcorcón, Barcelona, Madrid, Málaga, Pamplona, Santander, Santiago de Compostela

2024-08-27

Active, closed

An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)

NCT06625398Thyroid Eye Disease

DrugVRDN-003

Viridian Therapeutics, Inc.

Phase 3

204

Santiago de Compostela, Córdoba, Madrid, Seville, Zaragoza

2024-08-27

Recruiting

A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events

NCT06500884Multiple Myeloma

DrugsRamantamig·Talquetamab

Janssen Research & Development, LLC

Phase 2

210

Badalona, Barcelona, El Palmar, Jerez de la Frontera, Madrid, Pozuelo de Alarcón, Salamanca

2024-08-26

Active, closed

A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)

NCT06564311Relapsing Multiple Sclerosis

DrugObexelimab

Zenas BioPharma (USA), LLC

Phase 2

Madrid, Málaga, Murcia, Seville, Valencia

2024-08-26

Active, closed

A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma

NCT06413498Multiple Myeloma

DrugsAnitocabtagene Autoleucel·Carfilzomib·Pomalidomide·Bortezomib

Kite, A Gilead Company

Phase 3

452

Badalona, Barcelona, El Palmar, Madrid, Pamplona, Salamanca, Santander, Seville

2024-08-23

Active, closed

A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors

NCT06533059Cancer, Breast Cancer, Endometrial Cancer, Metastatic Cancer

Alterome Therapeutics, Inc.

Phase 1

110

Barcelona, Madrid

2024-08-22

Recruiting

Abbott Structural Heart Device Registry

NCT06590467Heart Diseases, ASD - Atrial Septal Defect, VSD - Muscular Ventricular Septal Defect, PFO - Patent Foramen Ovale

Abbott Medical Devices

Observational

2,500

Esplugues de Llobregat, Oviedo, Seville, Madrid

2024-08-21

Recruiting

CEB-01 in Locally Resectable Pancreatic Cancer

NCT06538857Pancreatic Carcinoma

DrugCEB-01

CEBIOTEX

Early Phase 1

Barcelona, Madrid, Seville, Valencia

2024-08-20

Recruiting

A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists

NCT06033950Heart Failure

DrugFinerenone

Colorado Prevention Center

Phase 3

2,600

Girona, A Coruña, Santiago de Compostela, Madrid, Majadahonda, Málaga, Manises, Valencia

2024-08-20

Active, closed

A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma

NCT06577025Multiple Myeloma

DrugsCilta-cel·Talquetamab·Teclistamab·Bortezomib

Janssen Research & Development, LLC

Phase 2

Madrid, Salamanca, Santander

2024-08-20

Recruiting

A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis

NCT06461897Atopic Dermatitis

DrugsUpadacitinib·Dupilumab

AbbVie

Phase 3

675

Esplugues de Llobregat, Madrid, Valencia, Zaragoza

2024-08-19

Recruiting

Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)

NCT06371417Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP), Behçet's Syndrome (BS), Dermatomyositis (DM)

DrugRAY121

Chugai Pharmaceutical

Phase 1

144

Pamplona, Madrid, Barcelona, Córdoba, Seville, Valencia

2024-08-19

Recruiting

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

NCT06395103B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma

DrugZilovertamab vedotin

Merck Sharp & Dohme LLC

Phase 1/2

Esplugas de Llobregat, Madrid, Valencia, Barcelona

2024-08-16

Active, closed

A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.

NCT06247995Breast Cancer

DrugsGa-NeoB·Lu-NeoB·Capecitabine

Novartis Pharmaceuticals

Phase 1/2

L'Hospitalet de Llobregat, Barcelona, Madrid

2024-08-14

Recruiting

A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

NCT06435429Metastatic HER2-positive Breast Cancer

DrugsZanidatamab·Eribulin·Vinorelbine·Trastuzumab

Jazz Pharmaceuticals

Phase 3

550

A Coruña, Badajoz, Barcelona, Elche, Granada, Madrid, San Cristóbal de La Laguna, Seville

2024-08-13

Recruiting

Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

NCT06545942Advanced Solid Tumor, Metastatic Solid Tumor, Prostate Cancer, Pancreas Cancer

DrugOlaparib

MOMA Therapeutics

Phase 1

220

Barcelona, Madrid

2024-08-13

Recruiting

Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

NCT06467357Biliary Tract Cancer

DrugsRilvegostomig·Trastuzumab deruxtecan·Durvalumab·Gemcitabine

AstraZeneca

Phase 3

620

Barcelona, Madrid, Málaga, Santander

2024-08-12

Recruiting

A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

NCT06549595Untreated Follicular Lymphoma

DrugsSurovatamig·R-Chop

AstraZeneca

Phase 3

1,018

Barcelona, El Palmar, Girona, Las Palmas de Gran Canaria, Madrid, Oviedo, Pamplona, Santander

2024-08-07

Active, closed

M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)

NCT06421935Advanced Solid Tumor

DrugsHRS-1167·Tuvusertib·Prednisone/Prednisolone·Abiraterone

EMD Serono Research & Development Institute, Inc.

Phase 1

Barcelona, Madrid, Pozuelo de Alarcón

2024-08-07

Active, closed

Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)

NCT06162572Non-small Cell Lung Cancer (NSCLC)

DrugsS095029·Cemiplimab

Servier Bio-Innovation LLC

Phase 1/2

102

Barcelona, Madrid, Málaga, Valencia

2024-08-07

Recruiting

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

NCT06428019Chronic Lymphocytic Leukemia

DrugsAcalabrutinib·Obinutuzumab·Venetoclax

AbbVie

Phase 3

170

Santiago de Compostela, Majadahonda, Pamplona, Madrid, Seville

2024-08-05

Active, closed

Iptacopan in Patients With ANCA Associated Vasculitis

NCT06388941Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis

DrugsIptacopan·Rituximab

Novartis Pharmaceuticals

Phase 2

Plasencia, Pamplona, Madrid

2024-08-05

Recruiting

Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

NCT06380751Advanced Breast Cancer

DrugsSaruparib·Camizestrant·Exemestane·Anastrozole

AstraZeneca

Phase 3

788

A Coruña, Barcelona, Cáceres, Granada, L'Hospitalet de Llobregat, Madrid, Málaga, Pamplona

2024-08-01

Active, closed

An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study

NCT06534892Respiratory Syncytial Virus Infections

DrugRSVPreF3 OA vaccine

GlaxoSmithKline

Phase 3

10,212

Santiago de Compostela, Centelles, Vic, Majadahonda, Alcorcón, Barcelona, Madrid, Valencia

2024-08-01

By invitation

Use of Machine Learning Techniques for Serial Assessment of Systemic Inflammatory Markers in Breast Cancer Patients

NCT06447532Breast Cancer

Federal University of São Paulo

Observational

4,500

Madrid

2024-08-01

Not yet open

Beta-Blockers in Takotsubo Syndrome Study

NCT06509074Takotsubo Cardiomyopathy, Beta-blockers, Echocardiography, Left Ventricular Function

DrugBeta blocker

Spanish Society of Cardiology

Phase 4

200

Madrid

2024-08

Active, closed

A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy

NCT06440967Hot Flashes

DrugsFezolinetant·Tamoxifen

Astellas Pharma Global Development, Inc.

Phase 3

982

Barcelona, Elche, Girona, Granada, Jaén, León, Madrid, Majadahonda

2024-07-31

Active, closed

A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.

NCT06517758Generalized Myasthenia Gravis

DrugIptacopan

Novartis Pharmaceuticals

Phase 3

146

Santiago Compostela, L'Hospitalet de Llobregat, Alicante, Barcelona, Lleida, Madrid, Málaga, Valencia

2024-07-31

Recruiting

Investigational Trial to Evaluate Safety and Tolerability of Treprostinil in Children Diagnosed With PAH

NCT06350032Pulmonary Arterial Hypertension

AOP Orphan Pharmaceuticals AG

Phase 3

Madrid

2024-07-31

Recruiting

HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of Life

NCT05373264ADPKD

DrugHydrochlorothiazide

University Medical Center Groningen

Phase 3

300

Alcázar de San Juan, Barcelona, Madrid

2024-07-31

By invitation

A Prospective Non-interventional Observational Study to Observe Long-term Treatment and Outcomes in Pulmonary Arterial Hypertension (PAH) Patients

NCT06445673Pulmonary Arterial Hypertension

AOP Orphan Pharmaceuticals AG

Observational

110

Barcelona, Madrid

2024-07-31

Recruiting

LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

NCT06216301Metastatic Non-small Cell Lung Cancer

DrugPembrolizumab

NovoCure GmbH

Phase 3

734

Elche, Seville, Barcelona, Torrejón de Ardoz, Lleida, Madrid, Málaga, Pamplona

2024-07-31

By invitation

Long-term Safety and Tolerability of BHV-7000

NCT06443463Focal Epilepsy

DrugOpakalim

Biohaven Therapeutics Ltd.

Phase 2

660

Badalona, L'Hospitalet de Llobregat, Pamplona, Vigo, Barcelona, Granada, Madrid, Málaga

2024-07-30

Active, closed

A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)

NCT06510816Geographic Atrophy

DrugVonaprument

Annexon, Inc.

Phase 3

659

Valencia, Barcelona, Córdoba, Madrid, Majadahonda, Sant Cugat del Vallès, Santiago de Compostela, Seville

2024-07-30

Active, closed

NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

NCT06379217Metastatic Neuroendocrine Prostate Cancer

Drugs[68Ga]Ga-PSMA-11·[177Lu]Lu-DOTA-TATE·[68Ga]Ga-DOTA-TATE·Ga-NeoB

Novartis Pharmaceuticals

Phase 1

L'Hospitalet de Llobregat, Madrid

2024-07-29

Active, closed

A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression

NCT06365853Recurrent Ovarian Cancer, Folate Receptor-Alpha Positive

DrugsMIRV·Mirvetuximab Soravtansine

AbbVie

Phase 2

108

Barcelona, Cáceres, Jaén, Madrid, Valencia

2024-07-29

Recruiting

Video Classification of Intubation in Spain (VCI)

NCT06537531Difficult Intubation

Clinica Universidad de Navarra, Universidad de Navarra

Observational

1,500

Madrid

2024-07-26

Recruiting

Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms

NCT06559306Depressive Disorder, Major

DrugSeltorexant

Janssen Research & Development, LLC

Phase 3

752

Barcelona, Bilbao, Collado Villalba, Madrid, Torrevieja

2024-07-25

Active, closed

A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

NCT06459180Cervical Cancer

DrugsTisotumab Vedotin·Vinorelbine·Topotecan·Sacituzumab tirumotecan

Merck Sharp & Dohme LLC

Phase 3

686

Barcelona, L'Hospitalet de Llobregat, Girona, Madrid, Valencia, Córdoba

2024-07-24

Active, closed

A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)

NCT06355531Progressive Supranuclear Palsy

Ferrer Internacional S.A.

Phase 2

241

A Coruña, Badalona, Barakaldo, Barcelona, Madrid, Pamplona, Seville, Valencia

2024-07-23

Recruiting

A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

NCT06362252Extensive Stage-small Cell Lung Cancer

DrugsIfinatamab Deruxtecan·Atezolizumab·Carboplatin

Daiichi Sankyo

Phase 1/2

123

Barcelona, Girona, L'Hospitalet de Llobregat, Madrid, Málaga, Seville, Vigo

2024-07-22

Active, closed

A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease

NCT06544616Alzheimer Disease

Janssen Pharmaceutica N.V., Belgium

Phase 2

Barcelona, Getxo, Lleida, Madrid, Pamplona, Pozuelo de Alarcón, Sant Cugat del Vallès, Terrassa

2024-07-22

Recruiting

Depemokimab Asthma Imaging and Bronchoscopy Sub-Study

NCT06979323Asthma

DrugDepemokimab

GlaxoSmithKline

Phase 3

150

Barcelona, Benalmádena, Madrid, Palma de Mallorca, Santander

2024-07-19

Recruiting

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

NCT06282575Biliary Tract Cancer

DrugsZanidatamab·Durvalumab·Gemcitabine·Cisplatin

Jazz Pharmaceuticals

Phase 3

286

Santiago de Compostela, Barcelona, Córdoba, Madrid, Málaga, Pamplona, Seville, Valencia

2024-07-19

Active, closed

A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)

NCT06455202Chronic Spontaneous Urticaria

DrugBarzolvolimab

Celldex Therapeutics

Phase 3

976

Barcelona, Cadiz, Madrid, Pamplona, Pozuelo de Alarcón, Seville, Torrejón de Ardoz, Valencia

2024-07-19

Recruiting

A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

NCT06226883Inflammatory Bowel Diseases, Crohn's Disease

DrugZotemtegrast

Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)

Phase 2

385

Ferrol, Lleida, Madrid, Majadahonda, Seville, Valencia

2024-07-18

Recruiting

The Influence of the Vaginal Microbiome on Clinical Pregnancy in Patients Undergoing a Euploid Embryo Transfer

NCT06643065Vaginal Microbiome

Fundación IVI

Observational

1,573

Barcelona, Bilbao, Madrid, Málaga, Seville, Valencia, Vigo, Zaragoza

2024-07-17

Active, closed

A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)

NCT06483334Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma

DrugsEnfortumab Vedotin·Sacituzumab tirumotecan·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 1/2

Barcelona, Madrid

2024-07-17

Active, closed

Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)

NCT06456346Essential Thrombocythemia

DrugsBomedemstat·Hydroxyurea

Merck Sharp & Dohme LLC

Phase 3

300

Badalona, L'Hospitalet de Llobregat, Santander, Barcelona, Madrid, Marbella, Salamanca

2024-07-16

Recruiting

VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]

NCT06264180Advanced Melanoma

DrugsVusolimogene Oderparepvec·Relatlimab·Opdivo·Nivolumab

Replimune, Inc.

Phase 3

400

Barcelona, El Palmar, Madrid, Pamplona

2024-07-11

Active, closed

A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria

NCT06445023Chronic Spontaneous Urticaria

DrugBarzolvolimab

Celldex Therapeutics

Phase 3

963

Sabadell, Alicante, Barcelona, Córdoba, Madrid, Salamanca, Villarreal de Huerva

2024-07-11

Active, closed

Astroscape: A Study of Radiprodil on Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms in Patients With TSC or FCD Type II

NCT06392009Tuberous Sclerosis Complex, Focal Cortical Dysplasia

DrugRadiprodil

GRIN Therapeutics, Inc.

Phase 1/2

Barcelona, Madrid

2024-07-10

Recruiting

Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen

NCT06127407Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen

DrugIvosidenib

Servier Bio-Innovation LLC

Phase 3

136

Barcelona, L'Hospitalet de Llobregat, Madrid, Valencia

2024-07-09

Recruiting

A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)

NCT06024746Heart Failure

DrugsFinerenone·Dapagliflozin

Colorado Prevention Center

Phase 3

1,500

A Coruña, Santiago de Compostela, Madrid, Málaga, Manises, Valencia, Barcelona

2024-07-09

Recruiting

Talazoparib Plus Enzalutamide After Progression to Prior ARPi in Metastatic Prostate Cancer

NCT06582628Metastatic Prostate Cancer

DrugEnzalutamide

Fundacion Oncosur

Phase 2

Badalona, Barcelona, Sabadell, Santander, Cadiz, Madrid, Málaga, Barakaldo

2024-07-05

Active, closed

A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease

NCT06248619Thyroid Eye Disease

DrugTeprotumumab

Amgen

Phase 3

Madrid, Seville, Valencia

2024-07-05

Recruiting

A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1)

NCT06431594Solid Tumors, Neoplasms

DrugMocertatug rezetecan

GlaxoSmithKline

Phase 1

675

Barcelona, Córdoba, Girona, Madrid, Pozuelo de AlarcOn Madr

2024-07-02

Active, closed

Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease

NCT06293365Sjögrens Disease, Systemic Lupus Erythematosus, Rheumatoid Arthritis

DrugIanalumab

Novartis Pharmaceuticals

Phase 2

155

Santiago Compostela, A Coruña, Madrid

2024-07-02

Recruiting

Severe Complications During Ventricular Tachycardia or Premature Ventricular Complex Ablation

NCT07777744Ventricular Tachycardia (VT), Premature Ventricular Complexes

University Hospital, Basel, Switzerland

Observational

15,000

Madrid

2024-07-01

Recruiting

A Novel COMBinATorial Therapy With Albumin and Enoxaparin in Patients With Decompensated Cirrhosis at High-risk of Poor Outcome (COMBAT Trial).

NCT05895136Liver Cirrhosis, Decompensated Cirrhosis of Liver, Acute on Chronic Liver Failure (ACLF)

DrugsHuman albumin·Enoxaparin

European Foundation for Study of Chronic Liver Failure

Phase 2

Barcelona, Madrid

2024-07-01

Recruiting

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

NCT06465069Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm

Eli Lilly and Company

Phase 1

420

Barcelona, Madrid, Seville

2024-07-01

By invitation

Trajectories and Experiences of People With Multimorbidity in Spain (LOXO-MULTIPAP) Project: a Mixed Methods Study

NCT06478745Multimorbidity

Gerencia de Atención Primaria, Madrid

Observational

3,239,950

Madrid

2024-06-30

Active, closed

A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus

NCT06015737Cutaneous Lupus Erythematosus

AstraZeneca

Phase 3

339

Barcelona, Castellon, Granada, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Madrid, Majadahonda, Salamanca

2024-06-29

Recruiting

A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)

NCT06263231Sarcoma,Soft Tissue

DrugsINT230-6·Trabectedin·Pazopanib·Eribulin

Intensity Therapeutics, Inc.

Phase 3

333

Barcelona, Madrid

2024-06-28

Recruiting

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

NCT06324357Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma

DrugsZongertinib·Zanidatamab·Trastuzumab emtansine·MFOLFOX6

Boehringer Ingelheim

Phase 1/2

768

A Coruña, Barcelona, L'Hospitalet de Llobregat, Madrid, Seville, Valencia

2024-06-28

Active, closed

Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)

NCT06331312Polymyalgia Rheumatica

DrugSecukinumab

Novartis Pharmaceuticals

Phase 3

162

Sabadell, Bilbao, A Coruña, Madrid, Seville, Valencia

2024-06-28

Active, closed

A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

NCT06468228Hidradenitis Suppurativa

DrugLutikizumab

AbbVie

Phase 3

1,400

Sabadell, Santander, Manises, Madrid, Málaga, Valencia

2024-06-27

Recruiting

Colorectal Anastomosis Outcomes Using the Novel Powered Circular Stapler Compared With Manual Circular Staplers.

NCT06578065Colorectal Anastomosis

Fundación para la Investigación del Hospital Clínico de Valencia

Not applicable

540

Sabadell, Madrid, Murcia, Valencia

2024-06-27

Active, closed

ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack

NCT06118281Cardiovascular Risk, Acute Myocardial Infarction (AMI)

DrugZiltivekimab

Novo Nordisk A/S

Phase 3

10,000

Badalona, Málaga, El Palmar, A Coruña, Alicante, Barcelona, Lleida, Madrid

2024-06-25

Active, closed

A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)

NCT06496178Head and Neck Squamous Cell Carcinoma

DrugPetosemtamab

Merus B.V.

Phase 3

621

Barcelona, Madrid, Pamplona, Valencia

2024-06-25

Recruiting

Dose-finding for Dobutamine During Transitional Circulation in Very Preterm Infants

NCT06878742Infant, Premature, Diseases, Circulatory and Respiratory Physiological Phenomena

DrugDobutamine

Instituto de Investigación Hospital Universitario La Paz

Phase 1/2

Madrid

2024-06-24

Recruiting

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

NCT06393374Triple-Negative Breast Cancer

DrugsXeloda·Sacituzumab tirumotecan·Keytruda·Capecitabine

Merck Sharp & Dohme LLC

Phase 3

1,530

Seville, L'Hospitalet de Llobregat, A Coruña, Madrid, Majadahonda, Valencia, Barcelona

2024-06-24

Recruiting

A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)

NCT06455449Polymyositis, Dermatomyositis

AstraZeneca

Phase 3

240

A Coruña, Barcelona, Córdoba, L'Hospitalet de Llobregat, Madrid, Sabadell, Valladolid

2024-06-20

Recruiting

A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)

NCT06428409Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer

DrugsSacituzumab tirumotecan·Fluorouracil·Leucovorin·Adrucil

Merck Sharp & Dohme LLC

Phase 1/2

220

Madrid, Oviedo, Barcelona

2024-06-20

Active, closed

Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema

NCT05897424Alpha 1-Antitrypsin Deficiency, Emphysema

Sanofi

Phase 2

185

Santander, Madrid, Santiago de Compostela

2024-06-20

Recruiting

A Trial of Lu AG13909 in Adult Participants With Cushing's Disease

NCT06471829Cushing's Disease

DrugLu AG13909

H. Lundbeck A/S

Phase 2

Barcelona, Madrid

2024-06-19

By invitation

Study of SRP-1001 in Adult and Adolescent Participants With Facioscapulohumeral Muscular Dystrophy Type 1

NCT06131983Muscular Dystrophy, Facioscapulohumeral

Sarepta Therapeutics, Inc.

Phase 1/2

Barcelona, Madrid, Valencia

2024-06-19

Active, closed

A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma

NCT06388733Glioblastoma, GBM, Brain Neoplasms, Adult, Malignant, Brain Tumor

DrugsTemodar·Niraparib·Temozolomide

Ivy Brain Tumor Center

Phase 3

450

Barcelona, Córdoba, Girona, Madrid, Pamplona, Salamanca, Seville

2024-06-19

Recruiting

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

NCT06424288Heart Failure

DrugsVicadrostat·Dapagliflozin

Boehringer Ingelheim

Phase 3

6,712

Badalona, Barcelona, El Palmar, L'Hospitalet de Llobregat, Madrid, Málaga, Sanlúcar de Barrameda, Santiago de Compostela

2024-06-17

Recruiting

A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery

NCT06504147Peritoneal Carcinomatosis, Ovarian Cancer

Oncoinvent Solutions AS

Phase 2

114

Barcelona, Madrid, Pamplona, Valencia

2024-06-15

Recruiting

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab

NCT06389136Atopic Dermatitis

DrugsUpadacitinib·Dupilumab

AbbVie

Phase 3

200

Granada, Madrid, Valencia

2024-06-14

Recruiting

FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

NCT06303505Ovarian Cancer, Non-small Cell Lung Cancer

DrugTUB-040

Gilead Sciences

Phase 1/2

250

Madrid

2024-06-12

Active, closed

A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)

NCT06472076Lung Cancer, Non-Small Cell

DrugsBelrestotug·Dostarlimab·Pembrolizumab

GlaxoSmithKline

Phase 3

A Coruña, Aravaca, BaracaldoVizcaya, Barcelona, Jaén, Las Palmas de Gran Canar, Madrid, Oviedo

2024-06-10

Recruiting

A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis

NCT06311682Atopic Dermatitis

DrugTralokinumab

LEO Pharma

Phase 3

195

Alicante, Madrid, Valencia

2024-06-10

Recruiting

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

NCT06422143Non-small Cell Lung Cancer, NSCLC

DrugsSacituzumab tirumotecan·Nab-paclitaxel·Keytruda·Paclitaxel

Merck Sharp & Dohme LLC

Phase 3

851

Santiago de Compostela, Las Palmas de Gran Canaria, Málaga, Barcelona, Madrid, Seville

2024-06-10

Active, closed

Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

NCT06082167Head and Neck Squamous Cell Carcinoma

DrugsZanzalintinib·Keytruda·Pembrolizumab

Exelixis

Phase 2/3

600

A Coruña, Barcelona, Girona, Madrid, Pamplona, Seville, Valencia, Zaragoza

2024-06-07

Active, closed

A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT06425991Multiple Myeloma

DrugTeclistamab

Janssen Research & Development, LLC

Phase 1

108

Barcelona, Madrid, Pamplona, Pozuelo de Alarcón, Salamanca, Santander

2024-06-07

Active, closed

Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5

NCT06284122Follicular Lymphoma

DrugsBendamustin·Mosunetuzumab·Vincrystine·Obinutuzumab

The Lymphoma Academic Research Organisation

Phase 3

790

Albacete, Barcelona, Las Palmas de Gran Canaria, Lleida, Madrid, Marbella, Oviedo, Salamanca

2024-06-07

Recruiting

A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections

NCT06056297Neutropenia

X4 Pharmaceuticals

Phase 3

176

Barcelona, Cáceres, Córdoba, Las Palmas de Gran Canaria, Madrid, Santander, Seville, Valencia

2024-06-06

Active, closed

Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab

NCT06211036Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer

DrugsTarlatamab·Durvalumab

Amgen

Phase 3

563

Málaga, Seville, Barcelona, L'Hospitalet de Llobregat, Pamplona, Valencia, Madrid

2024-06-05

Recruiting

IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

NCT06112314Advanced Melanoma

DrugsBrenetafusp·Relatlimab·Opdivo·Nivolumab

Immunocore Ltd

Phase 3

680

Santander, El Palmar, A Coruña, Barcelona, Córdoba, Granada, Las Palmas de Gran Canaria, Madrid

2024-06-05

Active, closed

T-DXd Therapy for HER2-low Breast Cancer Patients With Brain Metastases

NCT06048718Breast Cancer, Metastatic Breast Cancer

DrugTrastuzumab deruxtecan

MedSIR

Phase 2

Alicante, Barcelona, Bilbao, Córdoba, Granada, Madrid, Seville, Valencia

2024-06-05

Recruiting

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

NCT06430801Crohn's Disease

DrugTulisokibart

Merck Sharp & Dohme LLC

Phase 3

1,200

Badalona, Barcelona, A Coruña, Majadahonda, Torrejón de Ardoz, Madrid, Pontevedra, Santa Cruz de Tenerife

2024-06-05

Recruiting

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

NCT06479135Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis, Primary Myelofibrosis

DrugsNavtemadlin·Jakavi·Ruxolitinib

Kartos Therapeutics, Inc.

Phase 3

600

Badalona, Barcelona, Cáceres, Las Palmas de Gran Canaria, Madrid, Málaga, Salamanca, Valencia

2024-06-03

Active, closed

A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

NCT06507306Solid Tumor, Adult

DrugsKQB198·Tagrisso·Amivantamab·Osimertinib

Kumquat Biosciences Inc.

Phase 1

Barcelona, Madrid, Málaga, Pamplona

2024-06-03

Recruiting

A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)

NCT06439277Obesity, Weight Gain

DrugTirzepatide

Eli Lilly and Company

Phase 3

300

Barcelona, Córdoba, Madrid, Málaga, Valencia

2024-06-03

Recruiting

Evaluate the Effectiveness of a Virtual Community of Practice

NCT06046326Chronic Diseases

Gerencia de Atención Primaria, Madrid

Not applicable

240

Madrid

2024-06-01

Recruiting

EMPATHY NSCLC: European Registry for Plasma-Based Molecular Profiling in Advanced NSCLC Patients

NCT07096258NSCLC (Advanced Non-small Cell Lung Cancer)

Hedera Dx SA

Observational

1,000

Madrid

2024-06-01

Recruiting

Treatment With Full-spectrum Cannabis Extract of Refractory Epilepsy Associated With Tuberous Sclerosis Complex (TSC)

NCT07403266Tuberous Sclerosis Complex (TSC)

Oils4Cure

Phase 3

Madrid

2024-06-01

Active, closed

A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease

NCT06401044Thyroid Eye Disease

DrugAMG 732

Amgen

Phase 1/2

Seville, Madrid, Valencia

2024-05-30

Active, closed

A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia

NCT05963074Leukemia, Lymphocytic, Chronic, B-Cell, Small Lymphocytic Lymphoma

DrugsVenclyxto·Ibrutinib·Venclexta·Venetoclax

Janssen Research & Development, LLC

Phase 2

333

Barcelona, Córdoba, Madrid, Santander, Santiago de Compostela

2024-05-30

Active, closed

ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer

NCT06328738HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2 Positive Solid Tumors, HER2 Amplification

DrugsELVN-002·Eribulin·Leucovorin·Trastuzumab

Enliven Therapeutics

Phase 1

275

Barcelona, Madrid, Pamplona, Valencia

2024-05-30

Active, closed

A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)

NCT06360354Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers

DrugsAnvumetostat·Modified FOLFIRINOX·Cetuximab·Nab-paclitaxel

Amgen

Phase 1

120

Seville, Barcelona, Madrid

2024-05-29

Recruiting

A Study of Pitolisant in Patients With Prader-Willi Syndrome

NCT06366464Prader-Willi Syndrome

DrugPitolisant

Harmony Biosciences Management, Inc.

Phase 3

134

Barcelona, Madrid, Málaga

2024-05-28

Active, closed

Clinical Trial to Evaluate BO-112 in Patients With Basal Cell Carcinoma (BCC)

NCT06422936Basal Cell Carcinoma

Highlight Therapeutics

Phase 2

Barcelona, Bilbao, Madrid, Salamanca, Valencia

2024-05-27

Recruiting

A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

NCT06419374Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis

DrugPegozafermin

89bio, Inc.

Phase 3

762

Almería, Badalona, Barcelona, Córdoba, Madrid, Málaga, Pontevedra, Santander

2024-05-24

Recruiting

Evaluation of the Effects of a Nutritional Intervention of Ketogenic Medium-chain Triglycerides and B-vitamins on Cognitive Functioning in Older Adults With Mild Cognitive Impairment (COGNIKET-MCI)

NCT06347315Mild Cognitive Impairment

Société des Produits Nestlé (SPN)

Not applicable

380

Alicante, Barcelona, Madrid, Salamanca, Sant Cugat del Vallès, Seville, Valencia

2024-05-24

Recruiting

First in Human Study of CDR404 in HLA-A*02:01 Participants With MAGE-A4 Expressing Solid Tumors

NCT06402201Select Advanced Solid Tumors

CDR-Life AG

Phase 1

Barcelona, Madrid, Valencia

2024-05-24

Recruiting

A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

NCT06345729Non-small Cell Lung Cancer

DrugsCalderasib·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

348

Las Palmas de Gran Canaria, Leganés, Madrid, Málaga, Barcelona, Seville

2024-05-24

Recruiting

Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

NCT06343402Non-small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer, NSCLC, KRAS G12C

DrugsBBO-10203·Pembrolizumab

TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

Phase 1

350

Horta-Guinardó, Barcelona, Madrid

2024-05-22

Recruiting

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

NCT06203210Small Cell Lung Cancer

DrugsAmrubicin·Ifinatamab Deruxtecan·Lurbinectedin·Topotecan

Daiichi Sankyo

Phase 3

540

Barcelona, Córdoba, Jaén, Jerez de la Frontera, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Madrid, Málaga

2024-05-21

Recruiting

Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).

NCT06133972Systemic Lupus Erythematosus

DrugIanalumab

Novartis Pharmaceuticals

Phase 3

550

Santiago Compostela, Badalona, Santander, Barcelona, San Sebastian Reyes, Madrid, Valencia

2024-05-21

Active, closed

Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients

NCT05735834Splenic Marginal Zone Lymphoma

DrugsTruxima·Zanubrutinib·Rituximab

International Extranodal Lymphoma Study Group (IELSG)

Phase 3

122

Barcelona, Bilbao, El Palmar, Madrid, Pamplona, Salamanca, San Sebastián, Valencia

2024-05-21

Active, closed

A Study of Revumenib in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias

NCT06226571Acute Myeloid Leukemias

DrugRevumenib

Syndax Pharmaceuticals

Phase 1

Santander, Barcelona, Cáceres, Granada, Madrid, Salamanca, Seville, Valencia

2024-05-21

Recruiting

VE303 for Prevention of Recurrent Clostridioides Difficile Infection

NCT06237452Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection

Vedanta Biosciences, Inc.

Phase 3

852

Badalona, Barcelona, Terrassa, San Sebastián, Madrid, Majadahonda, Seville, A Coruña

2024-05-20

Active, closed

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

NCT06157892Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms, HER2 Positive Breast Neoplasms

DrugsTucatinib·Disitamab Vedotin

Seagen, a wholly owned subsidiary of Pfizer

Phase 2

Barcelona, Bilbao, Erandio Bizkaia, Madrid, Valencia

2024-05-20

Recruiting

A Pilot Study to Evaluate the Systemic Effect of Oral Supplementation With AM3 in Patients With Metabolic Syndrome.

NCT06158152Metabolic Syndrome

Industrial Farmacéutica Cantabria, S.A.

Not applicable

Madrid

2024-05-20

Recruiting

Safety of IBD Drugs During Pregnancy and Breasfeeding: Mothers and Babies' Outcomes

NCT06337565Drusgs for IBD

Fundación de Investigación Biomédica - Hospital Universitario de La Princesa

Observational

1,000

Madrid

2024-05-20

Recruiting

Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)

NCT06353386Prostatic Neoplasms, Castration-Resistant

DrugsFludrocortisone acetate·Opevesostat·Cabazitaxel·Taxotere

Merck Sharp & Dohme LLC

Phase 1/2

220

L'Hospitalet de Llobregat, Madrid, Barcelona

2024-05-20

Recruiting

A Study of Sofe-M in Participants With Selected Advanced Solid Tumors

NCT06400472Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Non-Small-Cell Lung

DrugsSofe-M·Itraconazole·Bevacizumab·Carboplatin

Eli Lilly and Company

Phase 1

575

Barcelona, Madrid, Valencia

2024-05-20

Active, closed

Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

NCT06158841Multiple Myeloma

DrugsElotuzumab·Etentamig·Carfilzomib·Selinexor

AbbVie

Phase 3

421

Badalona, Ourense, León, Madrid, Salamanca, Valencia

2024-05-19

Active, closed

The OPBC-07/microNAC Study

NCT06529302Breast Cancer

University Hospital, Basel, Switzerland

Observational

2,000

Barcelona, Madrid

2024-05-15

Active, closed

A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy

NCT06321302Diabetic Retinopathy

Boehringer Ingelheim

Phase 2

190

Barcelon, Madrid, Sant Cugat Del Vallés, Valencia

2024-05-15

Recruiting

CHOP Plus Mosunetuzumab as First Line in Patients With Richter´s Syndrome: a Phase II Study of the Spanish Group of CLL

NCT06926205Richter Syndrome

DrugMosunetuzumab

GELLC (Grupo Español de Leucemia Linfocítica Crónica)

Phase 2

Barcelona, L'Hospitalet de Llobregat, Santander, Las Palmas de Gran Canaria, Madrid, Murcia, Marbella, Oviedo

2024-05-15

Active, closed

Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma

NCT05739942Newly Diagnosed and Recurrent Glioblastoma

DrugsGa-NeoB·Lu-NeoB

Novartis Pharmaceuticals

Phase 1

Granada, Badalona, L'Hospitalet de Llobregat, Madrid

2024-05-15

Active, closed

Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP

NCT06079359Hypophosphatasia

DrugALXN1850

Alexion Pharmaceuticals, Inc.

Phase 3

Madrid, Vitoria-Gasteiz

2024-05-14

Active, closed

INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC

NCT06295731Head and Neck Squamous Cell Carcinoma (HNSCC)

DrugsKeytruda·Pembrolizumab

Inhibrx Biosciences, Inc

Phase 2/3

410

Santiago, Barcelona, Pamplona, Madrid, A Coruña, Valencia

2024-05-14

Active, closed

Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

NCT06309966Focal Epilepsy

DrugOpakalim

Biohaven Therapeutics Ltd.

Phase 2/3

390

Badalona, L'Hospitalet de Llobregat, Pamplona, Vigo, Barcelona, Granada, Madrid, Málaga

2024-05-13

Recruiting

Local Excision for Organ Preservation in Early REctal Cancer With No Adjuvant Treatment

NCT05927584Rectal Cancer, Rectum Neoplasm

Fundación de Investigación Biomédica - Hospital Universitario de La Princesa

Observational

145

Madrid

2024-05-13

Active, closed

Autologous PRP and Focal Shock Waves for Erectile Dysfunction

NCT06433596Erectile Dysfunction

Elexial Research Limited

Not applicable

116

Madrid

2024-05-06

Active, closed

A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

NCT06238622Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis

DrugNerandomilast

Boehringer Ingelheim

Phase 3

1,666

Alicante, Barcelona, Bilbao, El Palmar, Galdakao, Granada, L'Hospitalet de Llobregat, Madrid

2024-05-06

Active, closed

A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)

NCT06356311Gastroesophageal Cancer

DrugsTrifluridine/Tipiracil·Sacituzumab tirumotecan·Irinotecan·Docetaxel

Merck Sharp & Dohme LLC

Phase 3

450

Santander, A Coruña, Pamplona, Oviedo, Barcelona, Madrid

2024-05-03

Active, closed

A Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease (AD)

NCT06402838Alzheimer's Disease

Hoffmann-La Roche

Phase 2

256

Sant Cugat del Vallès, Donostia / San Sebastian, Pozuelo de Alarcón, Salamaca, Barcelona, Córdoba, Madrid, Seville

2024-05-02

Recruiting

Early Closure of Left Atrial Appendage for Patients With Atrial Fibrillation and Ischemic Stroke Despite Anticoagulation Therapy

NCT05976685Ischemic Stroke, Atrial Fibrillation

DrugDOAC

Insel Gruppe AG, University Hospital Bern

Not applicable

482

Alicante, Barcelona, Madrid

2024-05-01

Not yet open

Phenotyping and Identification of Biological Markers in STXBP1 Encephalopathy

NCT06356233STXBP1 Encephalopathy With Epilepsy

Fundación Iniciativa para las Neurociencias (FINCE)

Observational

Madrid

2024-05-01

By invitation

A Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegtibatinase Treatment in Participants ≥5 to ≤65 Years of Age With Classical Homocystinuria (HCU) (ENSEMBLE)

NCT06431893Homocystinuria

DrugPegtibatinase

Travere Therapeutics, Inc.

Phase 3

100

Barcelona, Madrid, Santiago de Compostela, Seville

2024-04-30

Active, closed

A Study Evaluating APG777 in Atopic Dermatitis

NCT06395948Atopic Dermatitis

DrugAPG777

Apogee Therapeutics, Inc.

Phase 2

470

Santiago de Compostela, Badalona, Las Palmas de Gran Canaria, Alicante, Barcelona, Madrid, Zaragoza

2024-04-29

Recruiting

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

NCT06350097Non-small Cell Lung Cancer

DrugsDato-DXd·Osimertinib

AstraZeneca

Phase 3

582

A Coruña, Barcelona, Granada, Madrid, Majadahonda, Valencia

2024-04-29

Active, closed

S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP

NCT06188702MTAP-deleted Solid Tumors

DrugTNG462

Servier Bio-Innovation LLC

Phase 1/2

Madrid

2024-04-29

Active, closed

A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

NCT06346067Advanced or Metastatic NRAS-mutant Melanoma

DrugsNaporafenib·Temodar·Dacarbazine·Trametinib

Erasca, Inc.

Phase 3

Barcelona, Madrid, Oviedo

2024-04-29

Recruiting

A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)

NCT06338995Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

DrugLebrikizumab

Eli Lilly and Company

Phase 3

510

Andalucia, Barcelona, Cadiz, Galícia, Madrid, Pamplona

2024-04-29

Recruiting

Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

NCT05485961End Stage Kidney Disease

DrugClazakizumab

CSL Behring

Phase 2/3

3,110

Alcobendas, Barcelona, Córdoba, Girona, Granada, Guadalajara, Lleida, Madrid

2024-04-27

Active, closed

Heart Failure Patient Management and Interventions Using Continuous Patient Monitoring Outside Hospitals and Real-world Data

NCT07008729Chronic Heart Failure, Heart Transplant Recipient, Left Ventricular Assist Device

Puerta de Hierro University Hospital

Not applicable

390

Majadahonda, Madrid

2024-04-24

Active, closed

Dimethyl Fumarate in Adrenomyeloneuropathy

NCT06513533Adrenomyeloneuropathy Without Cerebral Involvement

DrugDimethyl Fumarate

Pujol, Aurora, M.D.

Phase 2/3

L'Hospitalet de Llobregat, Donostia / San Sebastian, Madrid

2024-04-23

Recruiting

Comparative Exercise-Induced Hypoalgesia in Upper and Lower Limbs: A Randomized Controlled Trial in Healthy Individuals

NCT06283186Healthy Subjects

Centro Universitario La Salle

Phase 1

Madrid

2024-04-23

Active, closed

Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta

NCT05972551Osteogenesis Imperfecta

DrugRomosozumab

Amgen

Phase 3

111

Barakaldo, Barcelona, Esplugues de Llobregat, Getafe, Valencia, Madrid

2024-04-22

Recruiting

A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer

NCT06385080Squamous Cell Carcinoma of Head and Neck

DrugsAmivantamab·Paraplatin·Taxol·Keytruda

Janssen Research & Development, LLC

Phase 1/2

287

Barcelona, Madrid

2024-04-22

Active, closed

To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations

NCT06194448Lung Cancer

DrugsTagrisso·Osimertinib·Pemetrexed·Paclitaxel

AstraZeneca

Phase 2

Barcelona, Donostia / San Sebastian, Granada, Madrid

2024-04-21

Recruiting

Effect on Periodontal Phenotype of Flapless Piezoincission During Orthodontic Treatment

NCT06315348Dental Malocclusion, Maxillary Deficiency

Universidad Complutense de Madrid

Not applicable

Madrid

2024-04-20

Recruiting

A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer

NCT06319820Non-Muscle Invasive Bladder Neoplasms

DrugGemcitabine

Janssen Research & Development, LLC

Phase 3

641

A Coruña, Alzira, Barcelona, Cadiz, Castellon, Jerez de la Frontera, Madrid, Málaga

2024-04-18

Active, closed

Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients

NCT06408935Crohn's Disease

DrugsTremfya·Guselkumab

Janssen-Cilag Ltd.

Phase 3

120

Alicante, Córdoba, Ferrol, Madrid, Valencia, Vigo

2024-04-17

Active, closed

A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy

NCT06253221Cardiomyopathy, Hypertrophic

DrugMavacamten

Bristol-Myers Squibb

Phase 3

Barcelona, Madrid

2024-04-17

Recruiting

Clinical Trial for the Evaluation of Customized 3D Printed NIV Nasal Masks in Premature Infants

NCT06224816Premature Lungs

Hospital Universitario 12 de Octubre

Not applicable

Madrid

2024-04-16

Active, closed

A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis

NCT06298552Generalized Myasthenia Gravis, gMG, Myasthenia Gravis, Generalized, Myasthenia Gravis

DrugEfgartigimod

argenx

Phase 3

119

Alicante, Barcelona, Lleida, Madrid, Santiago de Compostela, Valencia

2024-04-16

Recruiting

Study to Evaluate the Efficacy and Safety of Cetuximab in Combination with Encorafenib Plus Binimetinib As Induction Treatment in BRAF V600E Mutated MSS Initially Resectable or Potentially Resectable Advanced Colorectal Cancer

NCT06207656Colorectal Cancer

Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

Phase 2

Madrid

2024-04-16

Recruiting

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

NCT06312176Breast Neoplasms

DrugsLiposomal doxorubicin·Abraxane·Xeloda·Sacituzumab tirumotecan

Merck Sharp & Dohme LLC

Phase 3

1,200

Pozuelo de Alarcón, Madrid, Valencia, Barcelona, Córdoba, Seville

2024-04-14

Active, closed

A Study of Barzolvolimab in Patients With Prurigo Nodularis

NCT06366750Prurigo Nodularis

DrugBarzolvolimab

Celldex Therapeutics

Phase 2

140

A Coruña, Alicante, Barcelona, Madrid, Seville

2024-04-12

Active, closed

Effect of Probiotics on the Intestinal Microbiota of Pediatric Patients

NCT06352203Neurodevelopmental Disorders

ProbiSearch SL

Not applicable

Madrid

2024-04-12

Recruiting

Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function

NCT06307652Heart Failure and Impaired Kidney Function

AstraZeneca

Phase 3

3,850

A Coruña, Barcelona, Lugo, Madrid, Majadahonda, Seville, Valencia

2024-04-12

Recruiting

A Study of NILK-2301 in Patients with Locally Advanced or Metastatic Low Tumor Volume (LTV) Colorectal Cancer

NCT06663839Colorectal Cancer Metastatic

Light Chain Bioscience - Novimmune SA

Phase 1

Barcelona, Madrid

2024-04-12

Active, closed

Effect Partial Digested Triglycerides on Supply Long-chain Fatty Acids to Very Preterm Newborns

NCT07311382Plasma Concentration

Hospital Universitario La Paz

Not applicable

Madrid

2024-04-11

Recruiting

A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors

NCT06311578Neoplasms

DrugCetrelimab

Johnson & Johnson Enterprise Innovation Inc.

Phase 1

126

Barcelona, Madrid

2024-04-10

Recruiting

A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

NCT06330064Recurrent or Metastatic Solid Tumors

DrugIfinatamab Deruxtecan

Daiichi Sankyo

Phase 1/2

680

Barcelona, Madrid, Seville

2024-04-10

Active, closed

A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).

NCT06307431Renal Cell Carcinoma

DrugsIntismeran autogene·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 2

272

Madrid, Barcelona, Seville

2024-04-10

Recruiting

Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

NCT06236438Non-Small Cell Lung Cancer

DrugsLivmoniplimab·Budigalimab·Pemetrexed·Cisplatin

AbbVie

Phase 2/3

840

Santiago de Compostela, L'Hospitalet de Llobregat, Barcelona, Madrid, Valencia

2024-04-10

Active, closed

A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)

NCT06211764Non-Muscle Invasive Bladder Neoplasms

DrugsTAR-200·Mitomycin C·Gemcitabine

Janssen Research & Development, LLC

Phase 3

272

Badalona, Barcelona, Madrid, Málaga, Sabadell, Santander, Seville, Valencia

2024-04-09

Active, closed

An Open-label Study to Investigate ECUR-506 in Male Babies Less Than 9 Months of Age With Neonatal Onset OTC Deficiency

NCT06255782Ornithine Transcarbamylase Deficiency, Ornithine Transcarbamylase Deficiency Disease, Ornithine Carbamoyltransferase Deficiency (Disorder), Urea Cycle Disorders, Inborn

iECURE, Inc.

Phase 3

Barcelona, Madrid

2024-04-08

Active, closed

A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State

NCT06245408Sjögren's Syndrome (SS)

DrugDazodalibep

Amgen

Phase 3

434

Córdoba, Bilbao, A Coruña, Madrid, San Cristóbal de La Laguna, Santa Coloma de Gramenet(Barcelona), Seville, Vitoria-Gasteiz

2024-04-08

Recruiting

Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

NCT06276491Ovarian Cancer, Endometrial Cancer, Germ Cell Tumor, Testicular Germ Cell Tumor

DrugXmAb541

Xencor, Inc.

Phase 1

282

Barcelona, Madrid, Pamplona

2024-04-04

Active, closed

An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)

NCT06073132Generalized Epidermolysis Bullosa Simplex

TWi Biotechnology, Inc.

Phase 2/3

Madrid

2024-04-04

Active, closed

A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis

NCT06329401Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Pulmonary Fibrosis Secondary to Systemic Sclerosis, Pulmonary Fibrosis, Interstitial Lung Disease

DrugPirfenidone

Avalyn Pharma Inc.

Phase 2

375

Granada, Barcelona, Santander, Madrid, Málaga, Oviedo, Seville, Cadiz

2024-04-03

Recruiting

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

NCT06312137Non Small Cell Lung Cancer

DrugsSacituzumab tirumotecan·Pemetrexed·Gemcitabine·Paclitaxel

Merck Sharp & Dohme LLC

Phase 3

780

L'Hospitalet de Llobregat, Santiago de Compostela, Las Palmas de Gran Canaria, Pozuelo de Alarcón, Barcelona, Madrid

2024-04-03

Active, closed

A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours

NCT06305247Melanoma, Head and Neck Squamous Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer

Ipsen

Phase 1/2

Barcelona, Madrid

2024-04-03

Recruiting

A Study to Investigate Mechanisms of Resistance to Breast Cancer Therapies

NCT06274515Breast Cancer

Hoffmann-La Roche

Phase 4

320

Madrid, Seville, Valencia

2024-04-02

Recruiting

Exercise and Health Counseling in Pediatric Hematopoietic Stem Cell Transplantation

NCT06300515Hematopoietic System--Cancer

Alejandro Lucia

Not applicable

Madrid

2024-04-01

Active, closed

A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation

NCT06200207Heart Failure, Systemic Inflammation

DrugZiltivekimab

Novo Nordisk A/S

Phase 3

673

Castilleja de la Cuesta, Salamanca, Majadahonda, Madrid, Sanlúcar de Barrameda, Santiago de Compostela, Seville, Valencia

2024-04-01

Recruiting

A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors

NCT06265727Solid Tumor, Adult

DrugsCRB-701·Anti-PD-1

Corbus Pharmaceuticals Inc.

Phase 1/2

348

Barcelona, Madrid, Valencia

2024-04-01

Active, closed

Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)

NCT06291376Immunoglobulin A Nephropathy, IgAN

DrugRavulizumab

Alexion Pharmaceuticals, Inc.

Phase 3

584

A Coruña, Alcalá de Henares, Lleida, Madrid, Málaga, Murcia, Oviedo, Seville

2024-03-29

Active, closed

A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.

NCT06268873Chronic Kidney Disease and Hypertension

DrugBaxdrostat/dapagliflozin

AstraZeneca

Phase 3

2,554

A Coruña, Almería, Badalona, L'Hospitalet de Llobregat, Lugo, Madrid, Málaga, Palma deMallorca

2024-03-29

Active, closed

A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)

NCT06305767Bladder Cancer

DrugsIntismeran autogene·Enfortumab Vedotin·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 1/2

230

Badalona, Pozuelo de Alarcón, Madrid, Barcelona, Seville

2024-03-28

Active, closed

A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)

NCT06220201Multiple Sclerosis, Myasthenia Gravis

DrugsZola-cel·Fludarabine·Cyclophosphamide

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Phase 1

120

Barcelona, Madrid, Valencia

2024-03-28

Recruiting

Prehospital Resuscitation Intranasal Cooling Effectiveness Survival Study 2

NCT06025123Out-Of-Hospital Cardiac Arrest, Hypothermia, Ventricular Fibrillation

Karolinska Institutet

Not applicable

1,022

Madrid

2024-03-27

Recruiting

Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera

NCT06093672Polycythemia Vera

DrugHydroxyurea

Italfarmaco

Phase 3

220

Badalona, Alicante, Madrid, Málaga, Valencia

2024-03-26

Recruiting

A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)

NCT06163430Chronic Myeloid Leukemia, Chronic Phase, Chronic Myeloid Leukemia

Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 1/2

180

Barcelona, Las Palmas, Madrid, Zaragoza

2024-03-26

Recruiting

A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer

NCT07699328EGFR-Mutant Non-Small Cell Lung Cancer

Voronoi, Inc

Phase 1/2

315

Badalona, L'Hospitalet de Llobregat, Madrid, Málaga

2024-03-26

Recruiting

A Phase 1/1b Study of IAM1363 in HER2 Cancers

NCT06253871HER2 Mutation-Related Tumors, HER2, HER2-positive Breast Cancer, HER2 + Breast Cancer

Iambic Therapeutics, Inc

Phase 1

383

Barcelona, Madrid, Málaga, Seville, Valencia

2024-03-25

Active, closed

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy

NCT06333808HIV-1-infection

DrugsBictegravir·B/F/TAF·Lenacapavir

Gilead Sciences

Phase 3

577

Badalona Barcelona, Barcelona, Madrid, Seville, Valencia

2024-03-25

Active, closed

A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis

NCT06257875Ulcerative Colitis

DrugsLutikizumab·Humira·Adalimumab

AbbVie

Phase 2

156

Santiago de Compostela, Pamplona, Madrid, Seville

2024-03-23

Recruiting

Spanish-Portuguese Thrombotic Thrombocytopenic Purpura Registry

NCT05914441Purpura, Thrombocytopenic

Fundación Española de Hematología y Hemoterapía

Observational

300

Seville, L'Hospitalet de Llobregat, Barcelona, Guadalajara, Madrid, Murcia, Valencia

2024-03-22

Recruiting

A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

NCT06256588Neoplasms, Head and Neck

DrugDostarlimab

GlaxoSmithKline

Phase 3

864

BaracaldoVizcaya, Barcelona, Cartagena Murcia, HebrOn, Jerez de la Frontera, L'Hospitalet de Llobrega, Lugo, Madrid

2024-03-21

Recruiting

Neoadjuvant Radio-chemotherapy Safety Pilot Study in Patients With Glioblastoma

NCT06418113Glioblastoma, Glioblastoma Multiforme, Glioblastoma, IDH-wildtype, Radiotherapy; Complications

Hospital San Carlos, Madrid

Phase 1

Madrid

2024-03-21

Active, closed

Treatment With Peripheral Nerve Stimulation of the Pudendal Nerve in Patients With Erectile Dysfunction

NCT06397625Erectile Dysfunction, Electric Stimulation, Pudendal Nerve

Camilo Jose Cela University

Not applicable

Madrid

2024-03-20

Recruiting

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

NCT06072781Low Grade Serous Ovarian Cancer

DrugsAvutometinib·Defactinib·Pegylated liposomal doxorubicin·Anastrozole

Verastem, Inc.

Phase 3

270

El Palmar, Donostia / San Sebastian, Barcelona, Córdoba, Madrid, Santiago de Compostela, Valencia

2024-03-18

Recruiting

HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Sacituzumab Govitecan

NCT06236269Breast Cancer Stage IV

DrugSacituzumab Govitecan

SOLTI Breast Cancer Research Group

Phase 2

Badalona, L'Hospitalet de Llobregat, Barcelona, Granada, Madrid, Reus, Seville, Valencia

2024-03-15

Recruiting

Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study

NCT05904119First Progression of Glioblastoma

DrugLomustine

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3

411

Badalona, L'Hospitalet de Llobregat, Madrid

2024-03-15

Recruiting

An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants

NCT05835310Systemic Lupus Erythematosus

DrugAnifrolumab

AstraZeneca

Phase 3

100

Esplugues de Llobregat, Madrid, Málaga, Santiago de Compostela, Valencia

2024-03-14

Recruiting

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

NCT06318169Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis

DrugPegozafermin

89bio, Inc.

Phase 3

1,350

Barcelona, Córdoba, Madrid, Majadahonda, Málaga, Pontevedra, Santander, Santiago de Compostela

2024-03-13

Recruiting

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

NCT05939414Oligometastatic Prostate Cancer (OMPC)

DrugsPiflufolastat·Lu-PSMA

Novartis Pharmaceuticals

Phase 3

450

Granada, L'Hospitalet de Llobregat, Barcelona, El Palmar, Madrid, Seville, Valencia

2024-03-12

Recruiting

Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology

NCT06378190Refractory B-Cell Lymphoma, B-cell Lymphoma Recurrent

Instituto de Investigación Biomédica de Salamanca

Phase 1/2

Barcelona, L'Hospitalet de Llobregat, Madrid, El Palmar, Pamplona, Salamanca, Seville

2024-03-11

Active, closed

A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer

NCT06318273Metastatic Castration-Resistant Prostate Cancer

AbbVie

Phase 1

152

Barcelona, Madrid, Seville

2024-03-08

Recruiting

A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis

NCT05646381Aortic Stenosis

DrugPelacarsen

Novartis Pharmaceuticals

Phase 2

502

Cáceres, Córdoba, Madrid, Salamanca, Valencia

2024-03-07

Active, closed

A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors

NCT06238479Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm

Eli Lilly and Company

Phase 1

490

Barcelona, Madrid, Seville

2024-03-05

Active, closed

A Study of CYP-001 in Combination With Corticosteroids in Adults With High-risk aGvHD

NCT05643638Graft Versus Host Disease, Acute

Cynata Therapeutics Limited

Phase 2

Barcelona, Madrid, Murcia, Pamplona

2024-03-04

Active, closed

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

NCT06346392Gastric Cancer, Gastroesophageal Junction Cancer

DrugsSonesitatug Vedotin·Ramucirumab·Trifluridine/Tipiracil·Apatinib

AstraZeneca

Phase 3

594

Barcelona, Madrid, Ourense, Santander, Seville

2024-03-04

By invitation

Study of SRP-1003 in Participants With Type 1 Myotonic Dystrophy

NCT06138743Myotonic Dystrophy 1

Sarepta Therapeutics, Inc.

Phase 1/2

Almería, Barcelona, Madrid

2024-03-04

Recruiting

The STOP-MED CTRCD Trial

NCT06183437Heart Failure, Cardiotoxicity, Cardiac Toxicity, Antineoplastics Toxicity

Dinesh Thavendiranathan

Phase 4

335

Madrid

2024-03-04

Active, closed

First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228

NCT05737628Lymphoma

DrugsBYON4228·Rituximab

Byondis B.V.

Phase 1

Barcelona, Madrid

2024-03-04

Recruiting

Impact of the Menstrual Cycle in Reproductive Aged Women With Type 1 Diabetes Using a Closed Loop System (DIABETEXX/1).

NCT06338072Type 1 Diabetes

Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal

Observational

119

Madrid

2024-03-03

Active, closed

Effects of High-Intensity Laser Therapy on Tendon Tissue

NCT07817368Healthy Tendon

Centro Universitario La Salle

Not applicable

Madrid

2024-03-01

Recruiting

Effect of Acetazolamide on Diuresis and Natriuresis in Patients With Acute Heart Failure (SANDI STUDY)

NCT06285760Heart Failure, Persistent Congestion

DrugAcetazolamide

Puerta de Hierro University Hospital

Observational

Madrid

2024-03-01

Recruiting

"Multicenter Registry for Chest Wall Reconstruction Using Custom Dynamic Prostheses (PRODIPET)"

NCT07018960Chest Wall Tumors, Post-traumatic Syndrome, Malignant Bone Tumor of Chest Wall

Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal

Not applicable

Cruces, Las Palmas de Gran Canaria, Barcelona, Madrid, Alzira

2024-03-01

Active, closed

Myopia Adjustment Using Dual-intervention: Red-Light Therapy & Innovative Design in Orthokeratology

NCT06899139MYOPIA

Centro de Miopía Fernández-Velázquez

Not applicable

Madrid

2024-03-01

Active, closed

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor

NCT06241118Dermatitis Atopic

DrugsPimecrolimus·Amlitelimab·Tacrolimus

Sanofi

Phase 3

464

Badalona, Majadahonda, Seville, Alicante, Madrid

2024-02-29

Active, closed

A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)

NCT06335173Alzheimer Disease

Acumen Pharmaceuticals

Phase 2

542

Sant Cugat del Vallès, Cuarte de Huerva, Barcelona, Donostia / San Sebastian, Getxo, Madrid, Seville, Valencia

2024-02-29

Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Spanish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 13 October 2026. https://priyalifescience.com/clinical-trials-spain/city/madrid?page=3

Query this register directly

GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Spain and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,875 studies in total at the last sync on 11 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 3,046 of those studies with a site in Madrid.

How many clinical trials are recruiting in Madrid?

1,554 of the 3,046 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:18 UTC sync. A further 117 have not yet opened recruitment, 1,309 are active but closed to new participants, and 66 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.